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INTRODUCTION 
 
Enterococci are the fast emerging organisms causing serious nosocomial 
outbreaks. This is mainly due to acquiring virulence factors and multiple drug 
resistance pattern by the enterococcal species. Enterococci were considered as 
organisms of low virulence previously but recently, Enterococci has the ability 
to  acquire and share extrachromosomal elements encoding virulence traits or 
antibiotic resistance genes. This leads to their increased environmental survival  
and  their nosocomial infection. 
Enterococci are normal residents of oral cavity, gastrointestinal and 
biliary tracts and also seen  in vagina and male urethra. Enterococci are 
considered as opportunistic pathogen.
(49)
 
 
They are the common cause of  
nosocomial urinary tract, blood stream, surgical sites, intra abdominal and 
pelvic regions,  neonatal and central nervous system infections
(86)
. 
  In the French literature in 1899
(56)
 the term ente‟rocoque was used.  
The “Enterococcus” was coined by Thiercelin to state bacteria in pairs and 
short chains seen in human stools. The organism was initially designated 
„Micrococcus zymogenes‟ due to its fermentative properties.(56) The name 
Streptococcus faecalis  was used to describe an organism of fecal origin by 
Andrews and Harder in 1906 which  fermented  lactose and mannitol but not 
raffinose. Second organism, Streptococcus faecium differed from the  
S.faecalis  by the fermentation property which  was described by Orla Jensen in 
1919. In 1970 Kalina named S.faecalis and S.faecium as Enterococcus based 
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on the phenotypic characters and cellular arrangements.  In 1984, based on 
DNA-rRNA hybridization studies and 16S rRNA
(92)
 sequencing,
 
Schleifer and 
Kilpper Balz  allocated S.faecalis and S.faecium into a separate genus 
Enterococcus . 
Enterococcus genus include the Enterococcal members previously 
classified with the group D streptococci.About 80-90% of human Enterococcal 
infections is caused by the most common isolate E.faecalis.(Jett et 
al,1994
(40)
;Jones et al , 2004
(42)
    
E. faecium  second common among  Enterococcal infections  is isolated 
from 10-15% of infections.  Other Enterococcal species are infrequently 
isolated from human infections like E.durans, E. gallinarom,  E .casseliflavus. 
 
General characters of Enterococci: 
i) They are Gram positive cocci, usually appear oval in shape, arranged 
in pairs and short chains. 
ii)  All are facultatively anaerobic. 
iii) Most of them react with the Lancefield group D antisera. 
iv) All are non motile (except E. gallinarum and E. casseliflavus). 
v) They are able to grow at 10°C and 45°C and at pH 9.6. 
vi) Enterococci are usually alpha or gamma hemolytic on 5% sheep blood 
agar. Some produce beta hemolysis on  human, horse and rabbit blood. 
vii) They survive at the temperature of 60°C for 30 min. 
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viii) They are capable of growing in media containing 6.5% Nacl. 
ix) They are capable of hydrolyzing  esculin in the presence of 40% bile 
salts. 
x) They are capable of producing a Leucine aminopeptidase (LAP) and a 
Pyrrolidonyl arylamidase (PYR) (except for E. cecorum, E. columbae, 
E. pallens and E. saccharolyticus). 
• 3rd  most common cause for nosocomial  UTI(49) 
• 2 nd or 3 rd   most common cause for nosocomial bacteremia (49) 
• 5% to 20% of infective endocarditis caused by Enterococci (49) 
• Important feature of Enterococci are intrinsic resistance to various 
group of antobiotics  
• Enterococci has the ability to transfer the resistant genes to other 
bacteria. 
 
Virulence factors : 
1. Cytolysin / hemolysin :  It acts on human, rabbit, equine and bovine 
erythrocytes (but not sheep erythrocytes). The quorum sensing 
mechanism regulates expression of hemolysin 
(74)
 
2. Gelatinase :   The gelatinase, a protease  that has the capability of 
hydrolyzing gelatin, casein, collagen, hemoglobin and other peptides 
and gelE gene coding for gelatinase is involved in biofilm formation
(74)
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3. Aggregation substances(AS) : It is a surface bound, plasmid encoded 
protein that promotes clumping of the organisms to facilitate the 
plasmid exchange. Agg genes are involved in biofilm formation.  
Phagocytosis  is significantly resisted by Enterococci expressing  
aggregation substances . 
4. Extracellular surface protein (Esp) :  It helps the organisms evade 
antibodies by its ability to be retracted away from the cell surface. Esp 
gene is involved in biofilm formation.
 
  
5. Extracellular superoxide: Most E.faecalis and some E.faecium isolates 
from bacteremia produce large amounts of extracellular superoxide that 
may enhance Enterococcal virulence in mixed flora abscesses with 
Bacteroides fragilis. 
6. Lipoteichoic acid: It constitutes group D antigen of Enterococci and 
contributes to virulence by inducing the production of tumor necrosis 
factor (TNF) and interferon. 
7. Coccolysin: 50-65% of E. faecalis strains produce coccolysin, an 
extracellular metallo endopeptidase, involves in virulence by 
inactivating  endothelin. 
8. Biofilms:   The ability of Enterococci to cause device associated 
infections is enhanced by  the production of biofilms.
 
 
9. Cell wall carbohydrate and capsular polysaccharides 
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10. Gls24: It is a general stress protein that has important factor in virulence 
of E.faecalis in both mouse peritonitis and rat endocarditis models
96,97
 
 
Identification of Enterococcal species : 
            Facklam and Collins
(25)
 proposed physiological five groups to classify 
enterococcal species  based on  hydrolysis of arginine and acid production from 
mannitol and sorbose. Further speciation is based on acid production from 
sugars like arabinose, sorbitol, raffinose, sucrose, pyruvate, trehalose and 
motility and pigment production. 
 
 
 
 
 
 
 
 
 
 
 
6 
 
FACKLAM AND COLLIN FLOW CHART FOR IDENTIFICATION OF       
ENTEROCOCCUS SPECIES 
 
 
 
 
           
 
     
 
 
 
 
                    
 
 
 
                                                                 
 
 
 
                              
                                
 
 
 
Enterococcus species 
(Bile esculin +,  6.5%, Nacl+, PYR + 
MANNITOL 
Group III Arginine dihydrolase / Sorbose 
Group I Group II 
Sucrose / Raffinose 
Arabinose / Raffinose 
+/+   E. raffinosus 
+/-    E. avium (H2S+) 
-/+    E. malodoratus (H2S+) 
-/-    E. pseudoavium 
Growth in 
Pyruvate 
Growth in 
Pyruvate 
Motility 
E. hirae 
Yellow Pigment Arabinose 
E. dispar 
E. faecalis 
(asaccharolytic variants 
E. durans E. casseliflavus E. gallinarum 
Sucrose / 
melezitose 
E. seriolicida E. solitarius 
(+) (-) 
-/+ +/- 
+/+
  
-/- 
+
  
- 
+
  
-
  
+
  
-
  
+
  
-
  
+/+
  
-/-
  
Lactose 
E. mundtii E. faecalis E. faecium 
Yellow Pigment 
+
  
-
  
+
  
-
  
+
  
-
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Clinical presentations of Enterococcal diseases 
Endocarditis and Bacteremia: 
             Endocarditis and bacteremia are the usual presentations of enterococcal 
disease.  Enterococcus species are the third most common cause of nosocomial 
bacteremia. Sources of the bacteremia are usually the genitourinary and 
gastrointestinal tracts.  Intravascular or urinary catheters associated infection by 
enterococcus are mainly responsible for nosocomial bacteremia. Intra 
abdominal, pelvic, biliary tract, wounds (includes burns patients) and bones 
infection by enterococcus have also been documented as sources of the 
bacteremia. E.faecium bacteremia  have poor prognosis than E.faecalis because 
E.faecium  are  more resistant to antibiotics and are very difficult to treat.
(49)
 
Enterococci can affect both native and prosthetic valves and  cause both 
community and nosocomial associated endocarditis.  E.faecalis is being 
recovered  more frequently than E. faecium or other Enterococcal species. 
Most patients are elderly patient with comorbidities.  Procedures predisposing 
to Enterococcal endocarditis include cystoscopy, caesarean section, 
prostatectomy, transrectal prostatic biopsy, extracorporeal shock wave 
lithotripsy, colonoscopy, fiberoptic sigmoidoscopy transjugular intrahepatic 
portosystemic shunt (TIPS) and liver biopsy.  Mortality ranges from 11% to 
35% mainly due to heart failure or embolization
(56)
. 
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Urinary tract infections : 
             Enterococcal UTIs are well recognised infection in hospitals and 
usually associated with indwelling catheters, instrumentation and abnormalities 
of the genitourinary tract. Enterococci are the third most common organism 
causing  catheter associated UTI. Removal of the catheter may suffice to 
eradicate the presence of the organisms. Enterococci can also cause 
complicated UTIs with the development of pyelonephritis and perinephric 
abscesses and can lead to bacteremia. 
 
Meningitis : 
           Enterococci are uncommon causes of meningitis accounting for about 
0.3%-4% of meningitis. The most common species isolated is E.faecalis. Other 
species that can also cause meningitis. Presentation of meningitis may be 
Spontaneous and postoperative. The mortality rate approaches 20% and 
residual neurological sequelae may be seen. 
(56) 
 
Intra-abdominal and pelvic infections : 
           Enterococci are commensals of the gastrointestinal and genitourinary 
tracts and  commonly isolated from abdominal and pelvic infections, usually 
with Gram negative and anaerobic organisms.  Enterococci are capable of 
causing spontaneous peritonitis and empyema in cirrhotic and chronic kidney 
failure patients. Enterococci may also cause peritonitis associated with chronic 
ambulatory peritoneal dialysis. 
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Neonatal infections : 
        Enterococci are part of the normal adult vaginal flora and can be acquired 
by neonates during delivery.  The organisms have been associated with  6% of  
late onset sepsis,  9% of surgical site infections, 5% of pneumonia, 10% of  
bacteremia and 17% of  UTIs  in neonatal units.  Enterococcal infections are 
usually hospital associated.  Affected patients usually have a prolonged 
hospital stay, low birth weight, prior antibiotic therapy and several invasive 
procedures. 
 
Skin, soft tissue and other infections : 
          Enterococci have been associated with skin, soft tissue and wound 
infection.They have also been isolated from bone in osteomyelitis.
(56) 
 
ANTIMICROBIAL RESISTANCE OF ENTEROCOCCI 
Important feature of enterococci are that they are intrinsically resistant 
to various group of antibiotics like cephalosporins , clindamicin ,co-
trimoxazole and  low level resistant to aminoglycosides
(12,13)
. Due to this, it is 
very difficult to treat and eradicate enterococcal infection. Low-level resistance 
to all aminoglycosides is due to  the decreased  drug uptake in to the bacterial 
wall which is associated with the proteins involved in electron transport
(38)
. 
Enterococci has the ability to transfer the resistant genes to other bacteria. 
Emergence of vancomycin resistant Enterococci  in addition to the 
increasing incidence of high level aminoglycoside resistance  presents a serious 
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challenge for clinicians treating the patients with infections due to Enterococci . 
It is well noted that resistance to glycopeptide antibiotics has been transferred 
between Enterococcus species and from Enterococci to other gram-positive  
bacteria including Staphylococci, Streptococci and Listeria by means of 
exchange of resistance  genes by conjugation. 
Optimal antimicrobial treatment  for serious enterococcal infections 
requires  combinations of a cell wall–active agent, such as a penicillin 
,Ampicillin or a glycopeptide, with an aminoglycoside results in synergistic 
action which results in  bactericidal activity against this organism. The 
recommended aminoglycosides for treating  serious enterococcal infections are 
Gentamicin and Streptomycin. (CLSI GUIDELINES 2017 AND Mandell 
Douglas, and Bennett”s  principles and practice of Infectious Diseases) 
Enterococci have acquired aminoglycoside resistance genes that mediate 
production of aminoglycoside-modifying enzymes, which in turn eliminate this 
synergistic bactericidal effect. Detection of these aminoglycoside-modifying  
enzymes has resulted in the traditional approach for predicting bactericidal 
synergism in enterococci. 
High level aminoglycoside resistance : 
All   enterococci    have   low  level intrinsic  resistance     to   
Aminoglycosides, with  minimal  inhibitory  concentrations  (MICs)   ranging    
from    4 ug /mL to as high   as  256 ug/mL.  The MIC  of  gentamicin,  the  
most  commonly  used  aminoglycoside  against enterococci, typically ranges 
from 6 to 48 mg/mL. High level  Gentamicin resistance (HLGR) is defined by 
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the growth of  organism above concentrations of 500µg/ml (MIC>500µg/ml) of 
Gentamicin.
(12,13,49)
 
                Enterococci is thought to produce their low-level resistance to all 
aminoglycosides by limiting  drug uptake and it is associated with the proteins 
involved in   electron transport. The addition of an agent that interferes with  
cell wall synthesis, such as ampicillin (or vancomycin), markedly  increases 
uptake of the aminoglycoside, greatly enhance   the killing of the Enterococcus 
. Intrinsic resistance in E. faecalis is attributed to an inability of the 
aminoglycoside to enter the cell  as demonstrated in experiments by 
Moellering
(70)
 and colleagues in the early 1970s.  When enterococci were 
exposed to radiolabeled    aminoglycoside with or without penicillin, higher 
intracellular  aminoglycoside concentrations were achieved in the presence of 
the cell wall synthesis inhibitor. The combination of cell wall  active antibiotics 
and aminoglycosides  resulted in bactericidal activity (bactericidal synergism).  
Enterococci have acquired aminoglycoside resistance genes  that code 
various aminoglycoside-modifying enzymes, which result in very high 
resistance to aminoglycosides. 
Enterococci are intrinsically resistant to aminoglycosides  which do not 
cross the cell wall efficiently.The addition of cell wall  acting  antibiotic 
however sufficiently disorganizes the cell wall and then aminoglycosides gain 
access to the ribosomal target, thereby causing synergism
(38)
. 
But when Enterococci have acquired high resistance to aminoglycosides  
due to the presence of resistant determining genes that mediate production of 
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aminoglycoside modifying enzymes which eliminates synergistic bacteriacidal 
effect.  Serious Enterococcal infections like endocarditis, meningitis and sepsis 
are usually treated with combination of two antibiotics that is one acts on cell 
wall synthesis like beta lactam or glycopeptides (pencillin, ampicillin or 
vancomycin)   and  an  aminoglycoside  which  inhibits  bacterial  protein  
synthesis(i.e gentamycin or streptomycin ).
(11,12,13,92,49,88),
 These agents act 
synergistically to enhance killing of the bacteria, since  increased uptake of 
aminoglycoside in to the cell occur after cell wall damage by the beta lactam 
agent or glycopeptide antibiotics. 
All Enterococci  have low level resistance to gentamicin ( minimum 
inhibitory concentration 6ug to 48ug/ml )  due to decreased uptake in to cell 
which invalidates use of the disc test with usual concentrations (10 ug disc)of 
gentamicin. High level gentamicin resistance (minimum inhibitory 
concentration usually above 500 ug /ml ) testing with 120 ug disc is  the correct  
method when an Enterococcal strain is tested for antibiotic susceptibility
(12)
. If 
the Enterococci has high level  resistant to gentamicin, there is no synergism 
between cell wall acting antibiotic and gentamicin, then the combination 
therapy with the cell wall active agents will be ineffective. Therefore, it is 
important to detect the presence of high level gentamicin resistance in order to 
predict aminoglycoside synergy with cell wall acting antibiotics. Strains that 
show high level aminoglycoside resistance to gentamicin  posses one or more 
aminoglycoside modifying enzymes. There are three types of aminoglycoside 
modifying enzymes.  
13 
 
They are 
1. N-Acetyltransferases (AAC) – catalyzes acetyl CoA-dependent 
acetylation of an amino group 
2. O-Adenyltransferases (ANT) – catalyzes ATP-dependent adenylation of 
hydroxyl group 
3. O-Phosphotransferases (APH) – catalyzes ATP-dependent 
phosphorylation of a hydroxyl group
(16) 
These enzymes may make them resistant to one or more of a variety of 
other aminoglycosides . The genes coding for these enzymes are situated in the 
plasmid or transposon. In case of  High level Gentamicin resistance in 
Enterococci,the enzymes responsible for high level resistance are  N-
Acetyltransferases (AAC) and  O-Phosphotransferases (APH) . 
Aminoglycoside
(39) 
  Resistance gene       GM   Tobra    AK  Kana   Netil  Dibek  Strep    Arbek 
aac(6’)-Ie-aph(2”)-Ia   R       R        R       R       R       R        S             S 
aph(2”)-Ib                     R       R        S        R       R       R        S             S 
aph(2”)-Ic                     R       R        S        R       S        S        S             S 
aph(2”)-Id                     R       R        S        R       R       R        S             S 
aph(3)-IIIa                    S        S        R        R       S        S        S             S 
aac(6)-Ii                        S        R       S         R       R       NT     S           NT 
ant(3)-Ia                        S        S       S         S        S       S         R            S 
ant(4)-Ia                       S        R        R        R       S       NT      S             S 
ant(6)-Ia                       S        S         S        S        S       S        R             S 
(NOTE. NT, not tested; R, resistant to synergism; S, susceptible ) 
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The  four genes responsible for high level gentamicin resistant are
(39) 
  1.  aac(6’)-Ie-aph(2”)-Ia,     
 2.  aph(2”)-Ib,   
 3.  aph(2”)-Ic,    
 4.  aph(2”)-Id 
As stated in other reviews published in the  number of  literatures, 
enzymatic modification is the most important mechanism of aminoglycoside 
resistance in bacteria. 
The presence of different aminoglycoside modyfing enzymes each one 
capable to introduce a change  in the Gentamicin  molecule.  The capability of 
a bacterial isolate to both phosphorylate and acetylate aminoglycoside agents is 
usually justified by the presence of two different kind of enzymes, one 
belonging to the APH (phosphotransferases ) group, and another belonging to 
the AAC (acetyltransferase-) group. The bifunctional enzyme AAC(6')-
APH(2") (6-9), is peculiar because it posses both 6'-N-aminoglycoside 
acetyltransferase and 2"-O-aminoglycoside phosphotransferase activities which 
is present  in the same polypeptide. This enzyme is exclusive of Gram-positive 
bacteria and is responsible for high level resistance to aminoglycosides in the 
genera Staphylococcus and  Enterococcus.    
The first reports on enzymatic resistance of Gram-positive bacteria to 
aminoglycosides was  phosphorylation of kanamycin. In 1970s in France, and 
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later in other countries, strains of   Staphylococcus aureus and Staphylococcus 
epidermidis presented with a new pattern of aminoglycoside resistance. They 
were classified into two groups based on their resistance patterns: one group 
was resistant to   tobramycin and kanamycin , but susceptible to gentamicin, 
and  the other group was resistant to these  three antibiotics.  A 4'-O-
nucleotidyltransferase could explain the first resistance pattern and whereas 
two activities (phosphotransferase and acetyltransferase) explained the second 
type of resistant.  The phosphotransferase activity modifies the gentamicin 
components and the acetyltransferase inactivates other aminoglycoside 
antibiotics.  Biochemical and genetic profile analysis demonstrated that both 
activities are present in the polypeptide, that are coded by a single gene. The N-
terminal region of the polypeptide  chain  carries the acetyltransferase activity, 
and  C-terminal region carries phosphotransferase activity. The 
acetyltransferase acetylates the 6' amino group of the aminoglycosides , so it  
classified as a 6'-N-aminoglycoside acetyltransferase (AAC(6')). The 
phosphotransferase activity phosphorylates the 2" hydroxyl group of the 
aminoglycoside  hence  classified as  2"-O-aminoglycoside phosphotransferase 
APH(2").  Current data suggest that  aac(6)-Ie-aph(2) resistance gene results 
from fusion  of two individual resistance determinants. 
Enterococci that possess aac(6’)-Ie-aph(2”)-Ia are resistant to virtually 
all of the clinically available aminoglycosides, including gentamicin, 
tobramycin,amikacin, kanamycin, and netilmicin, but sensitive to streptomycin 
and arbekacin.
(39) 
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 Enterococci that possess aph(2”)-Ib  are resistant to   gentamicin, 
tobramycin, kanamycin, and netilmicin, but sensitive to amikacin streptomycin 
and arbekacin.
 (39) 
Enterococci that possess aph(2”)-Ic   are resistant to  the  following 
aminoglycosides, including gentamicin, tobramycin, kanamycin and sensitive 
to other aminoglycosides.
 (39) 
Enterococci that possess aph(2”)-Id  are resistant to  the  following 
aminoglycosides, including gentamicin, tobramycin, kanamycin, and 
netilmicin, but not amikacin streptomycin and arbekacin.
 (39) 
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 Among the four gene that are responsible for high level gentamycin 
resistance in Enterococci , prevalence of  aac(6‟)-Ie-aph(2”)-Ia gene is 79%, 
aph (2”)-Id 14%, aph(2”)-Ib 5%, aph(2”)-Ic 2% ( Joseph W.Chow et al 2000 
clinical infectious diseases society of America ). 
 In another study at Mongolia china, prevalence of  aac(6‟)-Ie-aph(2”)-Ia 
gene is 89.3%, aph(2”)-Id 10.7%, aph(2”)-Ib not detected  and  aph(2”)-Ic 
7.1%. 
In other study at Chennai prevalence of HLGR aac(6‟)-Ie-aph(2”)-Ia 
gene is 38.7%. The other genes  aph (2”)-Id , aph (2”)-Ib  and  aph(2”)-Ic  are 
not detected among isolated Enterococcal species.  
             Beta lactam antibiotics are not readily bactericidal for Enterococci 
hence the addition of an aminoglycoside achieves synergistic and bactericidal 
effect. Among the aminoglycosides, Gentamicin and Streptomycin are  
recommended for achieving this synergistic effect in clinical practice
(49,56)
.The 
emergence of HLR to both aminoglycosides was reported in 1983 and has 
increased since then in both E. faecalis and E. faecium.  High level  Gentamicin 
resistance (HLGR) is defined by the growth of  organism  above concentrations 
of 500µg/ml (MIC>500µg/ml ) of Gentamicin and High level  Streptomycin 
resistance (HLSR) is defined by the growth of  organism  above concentrations 
of  2000µg/ml (MIC>2000µg/ml) of Streptomycin on brainheart infusion agar 
or 1000µg/ml (MIC>1000µg/ml) of Streptomycin on brainheart infusion 
broth.
11,13,49,56
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 High level resistance to streptomycin can be due to mutations in the 
30S ribosomal subunit and to the presence of a streptomycin 6‟ adenyl 
transferase.
(27,28)
  Evaluation of HLGR in Enterococci has been the standard of 
care for treatment in endovascular  (or) serious infection. (Mandell Douglas 
&Benetts ).
 
 
Beta lactam resistance:  
Initially beta lactam antibiotics were the choice of antibiotics used in the 
treatment of Enterococcal infections.  Relative resistance to beta lactam drugs 
with minimal inhibitory concentration (MIC) of penicillin 10 to 100 times or 
more than of Streptococci is documented in Enterococci. Penicillins and 
carbapenems resistance  usually found in clinical isolates of E.faecium and rare 
in E. faecalis.  The mechanism of resistance in E.faecium involves mutations or 
overexpression of the PBP5 gene which decreases the affinity of its product to 
ampicillin. Beta lactam resistance in E. faecalis is also mediated by production 
of a beta lactamase enzyme.
(56) 
Eventhough Enterococci are normal flora in many sites in human it 
causes fatal infection among hospitalized patients. But only limited number of 
antibiotics are available to treat this infection .The best choice is the 
combination of cell wall acting agents and aminoglycosides ( gentamicin or 
streotomycin).   
Eventhough Enterococci is normal flora of many organ 
(GIT,ORAL,GENITAL etc) of human,it causes fatal infection like 
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endocarditis, meningitis,septicemia  and treating the infection, only limited 
antibiotics are available.  The best treatment for this fatal infection are the 
combination of cell wall acting agents & aminoglycosides. With this scenario  
the purpose of  these study is to isolate the Enterococci in various clinical 
specimen,speciation of isolated Enterococci, antibiotic susceptibility testing 
according to the CLSI guidelines with particular reference to use high level 
gentamycin disc (120 ug), and prevalence of high level gentamicin resistance 
among the isolated Enterococci and detecting the frequency of the common 
gene responsible for high level gentamicin resistance by molecular technique. 
Important clinical aspect of aac(6’)-Ie-aph(2”)-Ia gene in addition to 
gentamicin it confers resistance to other commonly used aminoglycosides like 
amikacin, tobramycin, kanamycin, netilmycin, and dibekacin except 
streptomycin.
(39) 
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AIMS AND OBJECTIVES 
 
i) To isolate and speciate Enterococcus from various samples collected 
from Govt rajaji hospital,Madurai by standard micobiological culture 
method and confirmation by biochemical tests. 
ii) To detect the pattern of antibiotic susceptibility among the isolated 
enterococcal species. 
iii) To find out prevalence of High level gentamicin resistance among the 
isolated enterococcal species by phenotypic screening methods.(Disc 
diffusion method (gentamicin 120 ug), E –test and agar dilution) 
iv) To find out antibiotic susceptibility pattern among the isolated  high 
level gentamicin resistant Enterococci 
v) Detecting the genes responsible for high level gentamicin resistance by 
molecular technique. (polymerase chain reaction) among the isolated 
High level gentamicin resistance(HLGR) Enterococci. 
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REVIEW OF LITERATURE 
 
In 10th edition of the Manual of Clinical Microbiology  by Murray
(59)
   
Enterococcus is closely  related to the “streptococci of fecal origin” or 
“enterococci”.  For a long time, Enterococcus  were considered  within the 
genus  Streptococcus, After the introduction of molecular methods  however, 
the enterococci  have  undergone  considerable  variation in taxonomy , 
splitting of   the  genus  Streptococcus, and the creation  of  Enterococcus as a 
separate genus, in 1984 . Streptococcus faecalis and Streptococcus faecium 
were the first species that was transferred in  to the new genus as Enterococcus 
faecalis and Enterococcus faecium, respectively. Subsequently, other  earlier 
streptococcal species and subspecies were transferred  in to  the genus of   
Enterococcus .    Since then, several new Enterococcus species have been 
described and included  in the genus  Enterococcus . 
Phylogenetic analysis based on the comparison of the 16SrRNA gene 
sequences showed that members of the genus Enterococcus are  closely related 
to the genera Vagococcus, Tetragenococcus, and Carnobacterium   than   to 
Streptococcus and Lactococcus, genera to which they are  phenotypically 
associated . 
The genus Enterococcus are gram-positive, catalase-negative cocci that 
occur singly or are in pairs or as short chains. Enterococcus cells are sometimes 
coccobacillary when smear are prepared from growth on solid medium but tend 
to be ovoid  or  chains when grown in liquid media.   Growth  on   blood agar 
22 
 
media after 24 h incubation  colonies are usually  1 mm to 2 mm in diameter 
.About 1/3
rd   
of  cultures of E. faecalis may be beta-hemolytic on agar 
containing rabbit, horse, or human blood  and  nonhemolytic on agar containing 
sheep blood. Sometimes  cultures of E. faecalis and Enterococcus durans may 
be  beta-hemolytic  regardless of the type of blood used. Other species are 
usually alfa-hemolytic or  nonhemolytic. 
Enterococci are facultative anaerobes with a homofermentative 
metabolism and produces l-lactic acid as the end product of glucose 
fermentation.  They can   ferment a wide range of carbohydrates to lactic acid, 
the enterococci are referred  as  lactic acid bacteria. Gas is not produced. They 
are  able to grow at temperatures ranging from 10 to 45°C,  and grow in broth 
containing 6.5% NaCl. Enterococci can  hydrolyze esculin in the presence  of 
bile salts ( 40%).  They can  hydrolyze leucine-b-naphthylamide by producing 
leucine aminopeptidase enzyme (LAP). Most enterococci, apart from 
Enterococcus cecorum, Enterococcus columbae, Enterococcus pallens, 
Enterococcus saccharolyticus, hydrolyze l-pyrrolidonyl-b-naphthylamide  by 
producing  pyrrolidonyl arylamidase enzymes (PYR) .  
Antimicrobial resistance may be either  intrinsic or acquired. Intrinsic 
resistance is due to the  inherent or natural chromosomally encoded character 
that  is present in  all or most of the Enterococci.  Specific  mechanism of 
intrinsic resistance to some of  the  antimicrobial agents are typically associated 
with a particular Enterococcal  species . In contrast, acquired resistance is more 
variable, resulting from  mutations in the existing  DNA or acquisition  of  new 
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genetic elements carried in plasmids or transposons.  Intrinsic resistance  in  
Enterococcal species involve  several  antimicrobial agents, particularly  the 
aminoglycosides and the beta-lactams. Because of the  intrinsic resistance to 
various  antimicrobial agents against enterococci  the recommended therapy for 
serious infections (i.e., endocarditis, meningitis, and other systemic infections), 
and   in  immunocompromised  patients, includes a combination  of drugs that  
acts on cell wall  such as a beta-lactam (usually penicillin or ampicillin) or 
vancomycin, and an aminoglycoside (usually gentamicin or streptomycin). This 
type of  combination can  overcome the intrinsic resistance exhibited by the 
Enterococcal species, and a synergistic bactericidal effect is achieved. This is 
due to  intracellular entry of the aminoglycoside is facilitated by the cell wall-
active drugs. 
In  Jawetz, Melnick & Adelberg's  Medical  Microbiology  the   
combinations of a cell wall–active agents like   penicillin or ampicillin or 
vancomycin  plus an aminoglycoside (streptomycin or gentamicin) is essential   
for severe Enterococcal infections, such as meningitis and  endocarditis. 
Although Enterococci having  intrinsic low-level resistance to aminoglycosides 
(MICs<500 μg/mL), they still effective because of the synergistic action when  
combined  with a cell wall–active agents and  an aminoglycoside. 
Some Enterococci have high-level resistance to aminoglycosides (MICs 
>500 μg/mL)  hence not susceptible to the synergism  because of the 
expression of  aminoglycoside-modifying enzymes,which inactivates 
Aminoglycosides even they entered into the cell. 
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The genes that code for these enzymes are usually located on plasmids 
or transposons. Resistance to the  gentamicin predicts resistance to other 
aminoglycosides except streptomycin. (Susceptibility to the  gentamicin does 
not predict susceptibility to other aminoglycosides.) Resistance to the 
streptomycin does not predict resistance to the other aminoglycosides.So, only 
the  streptomycin or gentamicin  is likely to have  synergistic activity with a 
cell wall–active agents  against Enterococci. 
Enterococci  that  causes severe infections should have susceptibility 
testing  for high-level aminoglycoside resistance( HLAR )  and  that  MICs 
usually above  500 μg/mLfor gentamicin and  above 1000 μg/mL for 
streptomycin in broth media in order to predict therapeutic efficacy. 
In CLSI  Clinical and Laboratory Standards Institute
(12,13)
 for 
Enterococcus spp., aminoglycosides (except for high-level resistance testing), 
cephalosporins,   trimethoprimsulfamethoxazole  and clindamycin,may appear 
active in vitro, but they are not effective clinically, and isolates should not be 
reported as susceptible. Synergy between ampicillin, penicillin, or vancomycin 
and an aminoglycoside can be predicted for enterococci by testing the organism 
against  high-level aminoglycoside (gentamicin and streptomycin)  
The results of ampicillin susceptibility tests should be used to predict the 
activity of amoxicillin. Ampicillin susceptibility  may be used to predict 
susceptibility to amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin,and 
piperacillin-tazobactam among non beta-lactamase producing enterococci. 
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Ampicillin susceptibility can be used to predict imipenem susceptibility, 
providing the  species is confirmed to be E. faecalis. 
Enterococci susceptible to penicillin are predictably suscept ble to 
ampicillin, amoxicillin, ampicillin-sulbactam,amoxicillin-clavulanate, 
piperacillin, and piperacillin tazobactam  for non beta-lactamase-producing  
Enterococci. However, Enterococci susceptible to ampicillin cannot be 
assumed to be susceptible to penicillin. If penicillin results are needed, testing 
of penicillin is required. 
Combination therapy with  ampicillin, penicillin, or vancomycin (for 
susceptible strains), plus  an aminoglycoside  is usually indicated for treatment 
of  serious  enterococcal  infection unless high-level resistance  (HLR) to both 
gentamicin  (HLGR) and streptomycin  (HLSR) is documented.The effect of  
such combinations  are predicted  in synergistic killing of the Enterococcus.  
Because  other aminoglycosides  antimicrobial  activities against enterococci 
are not superior to gentamicin and streptomycin, they need not be tested. High 
level gentamycin resistance ( MIC usually above 500 ug /ml ) testing with high 
content disc that is  120 ug disc is  the correct  method when an Enterococcal 
strain is tested for antibiotic susceptibility   testing  by  Kirby – Bauer disc 
diffusion method . In this method 6 mm is considered as Resistant, 7–9 mm 
considered  as inconclusive  and  ≥ 10 mm is considered as Susceptible. 
Minimum inhibitory concentration (MIC) correlates with this disc diffusion 
method are Resistant > 500 μg/mL   Susceptible  ≤500 μg/mL. 
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Cong-Ran Li, Xin-Yi Yang, Ren-Hui Lou, Wei-Xin Zhang et al
(19)
   
the aminoglycoside antibiotics have been known for more than 60 years, since 
the discovery of streptomycin in 1944 .Aminoglycosides are polycationic 
broad-spectrum bactericidal antibiotics that are used to treat a number of 
bacterial infections. The primary target of aminoglycosides is the 30S small 
subunit of ribosomes  . The  use of aminoglycosides is restricted by  the 
emergence of aminoglycoside-modifying enzymes (AMEs). 
The AMEs are composed of three families aminoglycoside   
nucleotidyltransferase, aminoglycoside    acetyltransferase (AAC), and 
aminoglycoside phosphotransferase(APH). Clinically, the bifunctional 
modifying enzyme AAC(6_)- APH(2_) is the most important  AME  in  
Staphylococcus aureus and Enterococcus  faecalis.  This enzyme is unique  as 
it has two activities of two classes of AMEs, an N-terminal [AAC(6_)-Ie] and a 
C-terminal APH [(APH(2_)-Ia]  and was believed  to have resulted from fusion 
of the aac and aph genes .  The two domains do not functionally interact but 
have intimate structural linkages that are important for its activity. The 
aac(6_)-aph(2_) genes can be  present  in both the R plasmids  and 
chromosomes  of aminoglycoside-resistant isolates, with  locations on 
transposons, like Tn4001 , Tn4031  and Tn5381. 
According to Esther Culebras , and Jose L.Martinez et al
(24)
 the 
expression of the bifunctional aminoglycoside modyfing enzyme 6'-N-
aminoglycoside acetyltransferase-2" -O-aminoglycoside phosphotransferase is 
the most important mechanism  of  high-level  aminoglycoside  resistance 
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(HLAR)  in  staphylococcus and  Enterococcus. The enzyme  is  unique  
because it  carries  two  different aminoglysoside-modifying activities located 
in different regions of the molecule. The gene aac(6')-aph(2") which encodes 
the synthesis of the enzyme is present in Tn4100-like  transposons  which  are 
inserted  both  in R plasmids  and the chromosomes of aminoglycoside-
resistant isolates. The genetic structure of aac(6')-aph(2")-containing isolates 
indicates that their origin is not clonal, but plasmid conjugation together with 
multiple insertion events are in the basis of the rapid spread of aminoglycoside 
resistance among Gram-positive bacteria. 
According to Monolekha Bhattacharya,a Marta Toth,a Clyde A. 
Smith,b Sergei B. Vakulenkoa et al  the main  mechanism of aminoglycoside 
resistance in Gram-positive and  Gram-negative bacteria is due to the 
production of aminoglycoside modifying enzymes, aminoglycoside 
phosphotransferases (APHs),  aminoglycoside acetyltransferases, (AAC) and 
aminoglycoside nucleotidyltransferases (ANT) These enzymes are capable to  
modify hydroxyl or amino groups on the drug which are important for its  
binding to the target site, the 30S subunit of the bacterial ribosome.  APHs are  
capable of phosphorylating the 4, 6, 9, 3, 2, 3 and 7  position  hydroxyl groups 
of various aminoglycosides  and  ATP is the major source of phosphate for 
these enzymes.  
Studies showed   that   2_-phosphotransferases [APH(2)], enzymes  are 
widely distributed in  staphylococcal  and enterococcal  isolates .They  
demonstrated that they can utilize GTP as a cosubstrate . Based on  these  
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studies  a new  nomenclature  for  the  APH(2_) enzymes  was proposed, that  
reclassified  the APH(2_)-Ia, -Ib, -Ic, and -Id enzymes as APH(2_)-Ia,-IIa, -
IIIa, and –Iva  enzymes, respectively.   Both  the  APH(2_)-Ia   and  APH(2_)-
IIIa  utilize  GTP  only  while APH(2_)-IIa and APH(2_)-IVa  can utilize both 
ATP and GTP as a cofactor. 
 
According to Raffaele Zarrilli1, Marie-Francoise Tripodi 
(101)
  High-
level gentamicin resistance (MIC > 500 µg/ml) is mainly mediated  by the  
aac(6)-Ie-aph(2)-Ia  gene, that  encodes the  bifunctional  enzyme  AAC(6)-
APH(2). In  recent years, three  more new aminoglycoside resistance genes   
[aph(2”)-Ib, aph(2”)-Ic  and  aph(2”)-Id]  were identified which  mediate 
resistance to gentamicin  have  been detected in enterococci species. Other 
genes that  confer resistance to various aminoglycosides but not to  gentamicin,  
aph(3)-IIIa and ant(4)-Ia, that encode the aminoglycoside modyfing enzymes  
(AME) have also been identified. The types and distribution of  resistance 
determining genes in enterococci species  vary in different geographical area. 
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According to Joseph W. Chow
(39)
  various aminoglycosides and their 
resistant gene pattern in enterococci as follows                      
Aminoglycoside 
 Resistance gene          GM   Tobra    AK  Kana   Netil  Dibe   Strep    Arbek 
aac(6’)-Ie-aph(2”)-Ia   R       R        R       R       R       R           S              S 
aph(2”)-Ib                     R       R        S        R       R       R          S              S 
aph(2”)-Ic                     R       R        S        R       S        S          S              S 
aph(2”)-Id                     R       R        S        R       R       R          S              S 
aph(3)-IIIa                    S        S        R        R       S        S          S              S 
aac(6)-Ii                        S        R       S         R       R       NT        S            NT 
ant(3)-Ia                        S        S       S         S        S       S           R             S 
ant(4)-Ia                       S        R        R        R       S       NT         S             S 
ant(6)-Ia                       S        S         S        S        S       S           R             S 
(NOTE. NT, not tested; R, resistant to synergism; S, susceptible ) 
 
  The gene responsible for high level gentamicin resistance are 
  1.   aac(6’)-Ie-aph(2”)-Ia,     2.  aph(2”)-Ib,   3. aph(2”)-Ic,    4.  aph(2”)-Id 
A study conducted by Seema sood, Meenakshi Malhotra et al 
91
showed 42.9% of E.faecium and 40% of E.faecalis were the predominant 
species isolated in clinical specimen. In blood culture, E.faecium was the 
commonest isolate. In pus and urine samples ,E.faecalis was  predominant
 
.Other species such as E.avium, E.mundtii, E.durans, E.dispar, E.raffinosus and 
E.gallinarum were also isolated
 .
.In a study at  New Delhi , E.faecium (66%) 
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was the most common species in blood samples .The next common species  
was E.faecalis(20%). A study at Chandigarh reported  E.faecalis (55%) 
followed by E.casseliflavus (24%) and E.faecium (12%)  from urinary 
 
tract 
infection. 
 YA marothi, H Agnihotri et al (2005)
(102)
 described two types of 
antimicrobial resistance in Enterococci – Intrinsic  and acquired resistance. 
Intrinsic resistance is chromosomally mediated and are species specific .It is  
present in all members of the species. Intrinsic antimicrobial resistance by 
enterococci was expressed to Penicillinase susceptible  penicillin (low level), 
Penicillinase  resistant penicillins, Cephalosporins, Aminoglycosides (low 
level), Lincosamides and   Clindamycin (low level).  Acquired resistance is 
mainly due to acquisition of new DNA or mutation in DNA. Examples of 
acquired resistance are resistance to Penicillin by beta lactamases, High Level 
Aminoglycoside Resistance,Vancomycin, Tetracycline, high level of 
Clindamycin , Chloramphenicol, and  Fluoroquinolone  resistance . 
In DK Mendiratta,  H Kaur et al  2008
(21)
 study showed that high 
level resistance to both  Gentamicin and Streptomycin was observed in 
Enterococcal isolates by means of both high content disc diffusion and agar 
dilution (Minimum inhibitory concentration) methods. E. faecium isolates 
(95.5%) showed higher high level aminoglycoside ( HLGR) resistance than E. 
faecalis (37.5%). E.faecium (59.1%) showed higher combined resistance to 
both the aminoglycosides as compared to E. faecalis (7.8%).  In E. faecium 
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High Level Gentamicin Resistance (HLGR) was higher (22.7%) than High 
Level Streptomycin Resistance (HLSR) (13.6%).
 
Baragundi MC, Sonth SB et al (2010)
(5)
 study, out of 120 
Enterococcal isolates from clinical sample 47.5% (57) are E. faecium , 44.16%( 
53)  are  E. faecalis, 4.16%(5) are E. mundti, 1.66%(2) are E. durans and 
0.83%(1)  are E. dispar.  High level aminoglycoside resistance (HLAR) was 
seen in  greater than 75% isolates for Gentamicin and in greater than 60% 
isolates for Streptomycin. Totally 47.18% isolates showed HLAR ( both to 
HLGR+HLSR).    
 Srujana Mohanty et al, Gupta et al
(93)
 study  also showed such high 
level aminoglycoside resistance (HLAR).  The treatment options are limited 
when there is loss of the synergism between aminoglycoside and the beta 
lactum drugs due to expression of aminoglycoside modifying enzymes  by the 
enterococcal species, because the treatment of choice for serious enterococcal 
infections like endocarditis ,meningitis and bacteremia. 
In the text book of  Bailey and Scott” diagnostic microbiology(8)   
variety of enterococcal species have been isolated   from various clinical 
speciemen  of  human infections.  E. faecalis and E. faecium  are the species 
most commonly encountered.   Among the two species, E. faecalis is the most 
commonly encountered, and  incidence of  E. faecium infections is on the rise 
in many of the hospitals.  Two additional  species, E. gallinarum and E. 
casseliflavus, also isolated from the intestinal infections. 
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In the Mandell Douglas, and Bennett”s  principles and practice of 
Infectious Diseases
(56)
  High level gentamicin resistance were reported in 
1979. Enterococcal species are intrinsic resistant to cephalosporins, clindamicin 
,co-trimoxazole and  low level resistant to aminoglycosides. The use of 
pencillin plus gentamicin therapy in  patient with HLGR result in failure. There 
was steady increase  in HLAR  during 1980 to 1990 reaching 30%. Prevalence 
of  HLSR was 40%. Rate of HLGR in E.faecalis exceeds 40% in Europe. 
According to Brian L. Hollenbeck and Louis B. Rice  et al
(11)
  
Intrinsic low level  resistance in E. faecalis is  attributed  to  an  inability  of  
the aminoglycoside to enter  in to the cell  as demonstrated in experiments by 
Moellering and  colleagues  in   1970. When  enterococci  were  exposed  to  
radiolabeled aminoglycoside with or without penicillin, higher intracellular 
aminoglycoside concentrations were reached  in the presence of  the cell wall 
acting  antibiotics. The combination of cell wall   active agents with  
aminoglycosides  resulted in bactericidal activity (bactericidal synergism). 
These studies  support  the observations of improved clinical outcomes with 
aminoglycoside-penicillin combination therapy. 
According to Mitra Khani,Mahdie Fatollahzade,Hamid et al
(61)
      
prevalence of isolates were 33 (24.1%) for E. faecium and 63 (46%) for E. 
faecalis. Eighty-nine percent of the isolates were high-level gentamicin 
resistant (HLGR), and 32.8% of E. faecium isolates and 67.2% of E. faecalis 
isolates carried aac(6’)-aph(2”). The prevalence of aph(3”)-IIIa among the E. 
faecalis and E. faecium isolates was 22.7% and 77.3%, respectively. 
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According to Haiying Niua, Hui Yub, Tangping Hua, Gailin Tiana et 
al
(35)
  the definition for   high-level gentamicin resistance (HLGR) is  MIC 
>500 µg/ml and  high-level streptomycin resistance (HLSR) is  MIC >µg2000  
g/ml). 
             The primer used to detect the AME in resistant enterococci are as 
follows    
 aac(6’)-Ie-aph(2”)-Ia    
                          F-CAGGAATTTATCGAAAATGGTAGAAAAG 
                          R-CACAATCGACTAAAGAGTACCAATC 
    aph(2”)-Ib 
                         F-CTTGGACGCTGAGATATATGAGCAC 
                         R-GTTTGTAGCAATTCAGAAACACCCT    
    aph(2”)-Ic  
                         F-CCACAATGATAATGACTCAGTTCCC  
                         R-CCACAGCTTCCGATAGCAAGAG  
    aph(2”)-Id  
                       F-GTGGTTTTTACAGGAATGCCATC 
                      R-CCCTCTTCATACCAATCCATATAACC 
 
According to Haiying Niua, Hui Yub, Tangping Hua, Gailin Tiana et 
al
(35)
, the predominant species observed  were E. faecium 53.8%  and E.faecalis  
28.2%. other species detected are E. avium  9.4%,E. gallinarum 5.1%, E. 
casseliflavus 2.6%, and E.durans  0.9%. In this study the prevalence of 
aminoglycoside modifying enzymes  are   42.7%  were High level gentamicin 
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resistance (HLGR)    and   27.4%  were   High  level  streptomycin  resistance  
(HLSR)  10.3%  of the  isolates were both HLGR and HLSR.  The highest 
resistance was observed among E. faecium, followed by E.faecalis and E. 
avium.  
Among the  HLGR isolates  89.3%  were carried  aac(6)-Ie-aph(2)-Ia,  
7.1% carried  aph(2”)-Ic,   10.7%  carried   aph(2”)-Id   and  25%   carried  
aph(3) IIIa.  but  aph(2”)-Ib was not detected .  
According to Niharika , Lall and Silpi et al
(71)
  Detection of High 
Level Aminoglycoside Resistance (HLAR) in Enterococcus species can predict 
the loss of synergy between cell wall active antimicrobial agents and 
Aminoglycosides. the present study was undertaken to detect the incidence of 
High level Aminoglycoside Resistant (HLAR). 
HLAR in Enterococcus species was detected by disk diffusion test using  
High level Streptomycin (HLS - 300 μg) disk and  High level Gentamicin 
(HLG - 120 μg) disk and Agar dilution method as per CLSI guidelines.  
High Level Aminoglycoside Resistance ( HLAR)  detected in 60.5%  of 
the Enterococcus strains. Among the HLAR  Enterococcus strains, 51.4%  were 
E. faecalis and 48.6%  were E. faecium.  Only High level Gentamicin 
resistance (HLGR), only High level Streptomycin resistance (HLSR) and both 
HLGR and HLSR producing  strains of E.faecalis  were detected as  38.9%,  
11.9%  and 49.2% respectively  among  the  HLAR positive E.faecalis . 
Similarly, among  HLAR producing E.faecium strains, 60.7%  produced only 
High level Gentamicin resistance (HLGR), 8.9%  produced only High level 
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Streptomycin resistance (HLSR) and  30.4%  produced both  HLGR and  
HLSR. 
According to   CAROL A. SPIEGEL et al (15) A total of 104 strains 
from 93 patients were studied; 97  (93.3%) were E. faecalis and 7(6.7%) were 
Enterococcus faecium  and  studied  for  high-level  resistance to  gentamicin 
and streptomycin and they found  28.3% and  32.6%  of  the  strains  were high  
level resistant to gentamicin and streptomycin, respectively. No strain was 
resistant to  both  drugs. 
According to  Verma D, Sinha S, Ved Prakash  et al 2013(100)  In total 
49% of Enterococci showed HLAR in their study set up out of which 4% were 
resistant to gentamicin only, 14% isolates were resistant to streptomycin only 
and  31% were resistant to both antibiotics.Such isolates may disseminate in  
health care facilities and therefore the  routine screening of  all  enterococcal 
isolates  with  High strength  Gentamicin  is  important. 
According to  Latika shah et al  in 2012(51) E.faecalis (75%)  was 
predominant isolate and E.faecium  was about 23%. .In their study they  
reported high HLAR among isolated enterococci were  53% for gentamicin and 
40 % for streptomycin with 8% VRE at their institute . 
According to Chandrim Sengupta, Anusha Venkatesan, Sangamitra.V et 
al  2011- 12(17)  study prevalence of  enterococcal species from various 
clinical specimen were  noted .  The contribution  of  E. faecalis  was 46.9% 
and E. faecium 33.3% ,E. durans 1.23%, E.avium 18.5%.  In  this  study 
29.62% of the enterococci showed HLAR.  The  HLAR  among  E. faecium 
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isolates was 29.62%  which was a  little  lower  than  E. faecalis  34.21% . It  
was  low  in  E.avium 12.5%.  
According to Gülçin Baldır, Derya Öztürk Engin, Metin Küçükercan et 
al (30) they studied the prevalence  of  High level Aminoglycoside Resistance 
(HLAR )  among the vancomycin resistant  enterococci (VRE) strains, and 
found that high-level gentamicin resistance (HLGR) was  83% and high-level 
streptomycin resistance (HLSR)  was 89%, and  association of  HLSR with 
HLGR was 78%. But in vancomycin sensitive  enterococci ( VSE) strains, 
HLGR was found to be 42% ,and  HLSR was 48%. Both  HLSR with HLGR 
was found to be 36%. HLAR in vancomycin resistant  enterococci ( VRE) 
strains was found to be higher as compared with vancomycin sensitive  
enterococci (VSE ) strains  (p <0.005). 
In the  study of Verma D, Sinha S, Ved Prakash  et al(100) ,they 
compared the high-level aminoglycoside  resistance  in the vancomycin 
resistant  enterococci (VRE) strains and the vancomycin sensitive enterococci 
(VSE) strains.  
In their study they screened   for HLGR AND HLSR  by disc diffusion 
method using  120 μg gentamicin and 300 μg of streptomycin disc. If disk 
diffusion result was inconclusive an agar screen test was performed on to Brain 
heart infusion Agar containing gentamycin 500μg/ml and streptomycin 
1000μg/ml. Any growth on the plate indicates that the strain was resistant .. 
Vancomycin resistance were screened by using Vancomycin screening agar 
(VSA) containing Vancomycin at concentration of 6 μg/ml. Growth of >1 
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colony was interpreted as Resistant and confirmation of VRE was done by 
Agar dilution method.  
They found that 49% of Enterococci showed HLAR and 12% were 
resistant to vancomycin with MIC≥ 32μg/ml.  In comparision,  High-level 
aminoglycoside resistance was 1.5 times more in vancomycin resistant  
enterococci (VRE) isolates  than  in  vancomycin sensitive enterococci ( VSE) 
isolates , this difference was statistically not significant.(p value>.05). High-
level aminoglycoside resistance to both streptomycin and gentamicin (HLGR 
and HLSR ) was more common in E. faecium than in E. faecalis strains. 
According to the study by Sarika jain ,Aswani kumar et al(87) the 
prevalence of enterococcal bacteremia in  hospitalized and outpatients in their 
study was 72% and 28%, respectively. Historically, the ratio of infection by  E. 
faecalis to those due to the other Enterococcus species was approximately 10:1 
but  there has been a progressive decline in recent years. It is true in their study, 
E. faecium  bacteremia was higher in prevalence than E. fecalis (53% and 33%, 
respectively). In this study,  the prevalence of relatively high proportion of E. 
faecium  was consistent with  those  reported  in other Indian studies from  
various  clinical  samples (40 to71%).  Many studies have also demonstrated 
that E. faecium is comparatively more resistant than E. faecalis. 
In their study  they demonstrated  high prevalence of  HLGR, HLSR, 
and HLAR (resistance to both gentamicin and streptomycin) among 
enterococci were 60%, 55% and 54%, respectively and  the detection of HLAR 
in hospitalized patients (92%) was high when compared  to community  
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acquired is also evident  that is 8%.  HLAR was more frequently observed in E. 
faecium isolates (71%) than other species. 
In the study of Jyothi P, Metri BC, Peerapur BV et al(41) among the 
enterococcal  isolates from the urinary tract infection , 63% were Enterococcus 
faecalis and 37 %were Enterococcus faecium. 49% of  isolates showed a high 
level resistance to gentamicin and/or streptomycin.In this study, HLAR both  
HLGR and HLSR were significantly higher (P < 0.05) in E. faecium which 
contribute 56.7% and E. faecalis contributed 44.4%.  In their observation that 
HLGR in enterococcal isolates from urinary tract infection were 14.2% and 
HLSR in enterococcal isolates from urinary tract infection were 11.4.%. 
According  to M. Emaneini, B. Khoramian, f. Jabalameli et al(63) the 
most prevalent species was E. faecalis (70.3%) followed by E. faecium (29.7%) 
which were  isolated from burn wound infections. All isolates were screened 
for genes encoding resistance to aminoglycoside.  The most prevalent 
aminoglycoside resistance gene  found was  aac(6‟)-Ie-aph(2‟‟)-Ia  and was, 
found in 96.2%  of the isolates. The ant (4‟) gene was detected in 62.9%  of  
the isolates. 
According to V.S. Randhawa, L. Kapoor, V. Singh & G. Mehta et al(83) 
the distribution of  high level gentamicin and high level streptomycin  
resistance  among  the  enterococcal  isolates  were   68% and 43%  
respectively and the distribution of  both  HLGR + HLSR were 43%. 
According to SR Moaddab  and  A Rafi  et  al(62)  Out of  enterococcus 
strains that were isolated , 45% were identified as E. faecalis, 43%  as E. 
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faecium  7%  , E. avium  3.5% as  E. raffinosus  0.5%  as   E. durans . The 
percentages of  high-level resistance to gentamicin and streptomycin were 16% 
and 15% for  E. faecium  in case of E. faecalis  13% and 17%,respectively. 
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MATERIALS AND METHODS 
 
           The present study was conducted in Government Rajaji Hospital, 
Madurai Medical College.  The study period was from Sep 2016 to August 
2017. Ethical committee clearance from the institution was obtained and 
informed written consent was received from the patients before collecting the 
specimens.  A total of 396 clinical samples blood, pus wound swab,and urine 
were collected from the patients admitted in various wards and OP of 
Government Rajaji Hospital, Madurai. 
 
Sample size and source : 
 Under aseptic precaution Urine, blood, pus and wound swab samples 
were collected from 396 patients attending in various wards of  Govt. Rajaji 
Hospital during the study period(Sep-2016 to Aug 2017) 
Inclusion criteria  
1. All age groups  and both sexs are included  
2. The patients attending outpatient department and in the wards with 
symptoms of Urinary tract infection, Sepsis, Wound infection,  
Meningitis and lower respiratory tract infection were included in this 
study. 
 
Exclusion criteria  
         Sputum and stool sample were excluded in this study.      
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Study type  
      Prospective study    
 
Study period 
                  Sep2016   –   August 2017   
 
Study population  
     396  samples were collected from the patients attended at various wards and  
op  in    GRH  attached  to Madurai Medical College. Madurai.  
  
Study centre  
     Institute  of  Microbiology, Madurai  Medical  College. Madurai.  
 
Collection of specimens: 
i)   Collection of blood samples: 
As per the standard guidelines, blood samples were collected by sterile 
aseptic precaution.  After wearing    sterile gloves  the skin over the 
venepuncture site was disinfected with 70% alcohol followed by 1% iodine  for 
1 minute and allowed to dry. Then  5 ml of blood was withdrawn and the blood 
was inoculated into  the  50ml of brain heart infusion broth. (BHI) and  the 
samples were transported to the microbiological laboratory immediately for 
processing.
(57)
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ii) Collection of urine samples : 
The female patients were instructed to hold the labia apart and  the male 
patients were asked to retract the foreskin of the penis, then washing the 
genitalia with soap and water. After several ml of urine have been passed, 
midstream clean catched urine   was collected into a sterile, leak proof, wide 
mouthed ,screw capped container. Then the collected urine samples were 
transported  to the laboratory within 30 minutes of collection. If there was a 
delay of more than two hours, the specimen were refrigerated at 4°C.
(57)                                                                                                          
 
 
iii)  Collection of wound swab samples : 
Two sterile cotton swabs were used to collect the samples from the 
wound sites of the patients. One was used for direct smear examination and the 
another swab were used for culture. The swabs were transported in sterile test 
tubes to the microbiologocal laboratory.
(57) 
 
iv) Collection of pus samples : 
The wound sites were decontaminated with 70% ethyl or isopropyl 
alcohol, then  washed  with sterile saline. After drying using a sterile syringe 
and needle, pus was aspirated and transported in a sterile container  to the 
microbiologocal laboratory.
(57) 
 
Processing of Samples : 
 The collected pus samples were properly labelled and registered with 
Name, age, sex and IP/OP no. of the patient, date and time of collection and 
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time of receiving the clinical samples. The  clinical data of the patients were 
also registered. Then the samples were  transported to the microbiology 
laboratory and processed immediately. 
 
Blood samples : 
         Inoculated  Brain heart infusion (BHI) broths were incubated at 37°C for 
18-24 hrs. After that, the broths were examined for turbidity and subcultured 
onto the Nutrient agar plate, MacConkey agar  plate and Blood agar plate for 
the isolation of organisms.   
 
Urine samples : 
        Wet mount and gram staining were performed from  uncentrifuged urine 
and the urine samples were inoculated on to the  Cystine lactose electrolyte 
deficient medium ( CLED) with the calibrated loop. Before inoculation, urine 
was mixed thoroughly. The calibrated loop was inserted vertically into the 
urine container.  The centre of the CLED  plate surface was touched with the 
loop and the inoculation was spread across the diameter of the entire plate.  
Without flaming  the loop was drawn across the entire plate, and crossing 
numerous times in order to produce isolated colonies.  The plates were then  
incubated at 37°C for 18-24 hours. A colony count of >10
5
 CFU/ml  was  
indicative of significanct bacteriuria 
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Wound swab and pus samples : 
 Direct Gram stain was done from wound swab and pus samples.Then 
the samples were  inoculated on to the Nutrient agar plate, MacConkey agar  
plate and Blood agar plate for the isolation of organisms.                                                               
 
Culture identification : 
After 24 hrs of incubation at 37°C, plates were examined for the 
presence of growth and the organisms were identified as follows, 
 
Identification of Enterococcus species: 
1. Nutrient agar plate :        Tiny, opaque colonies 
2. MacConkey agar plate :  Tiny, magenta pink  colonies 
3. Blood Agar plate  :          alpha / beta / non hemolytic colonies 
4. Gram staining :               Gram positive cocci in pairs and short chains. 
5.  Catalase test :                  Negative 
6.  Bile esculin test :           hydrolyze esculin in the presence of 40% 
                                        bile  -  blackening of the medium. 
7. 0.04% Tellurite agar produces black coloured colonies. 
8. Salt tolerance test :        Growth in 6.5% sodium chloride (Nacl) broth. 
9. Heat tolerance test :    Growth were detected before and after heating at  
a temperature of 60° C for 30 minutes in a water bath. 
10. Mannitol motility medium : Non motile, ferment mannitol by producing 
acid only. 
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11. Arginine dihydrolase test – Hydrolyses arginine – produces deep purple 
colouration after initial colour change to yellow. 
12. Carbohydrate (1%) fermentation  test – differs in various species. 
 
Species identification of Enterococcus 
 Enterococcal species were identified by  biochemical tests such as acid 
produced from sugars like arabinose, mannitol, pyruvate, Sucrose,and Sorbose, 
Raffinose, Sorbitol and NH3 produced from arginine, esculin hydrolysis in the 
presence of 40% bile, ability to grow in 6.5% Nacl broth, presence of 
Pyrrolidonyl peptidase enzyme (PYRase) and Leucine aminopeptidase 
enzymes (LAP), motility and pigment production. Facklam and Collin flow 
chart for identification of Enterococcus species was followed. 
 
Identification Tests  
1. Gram staining :  
 Gram positive elongated cocci arranged in pairs and short chains were 
identified  presumably  as Enterococci. 
 
2.Catalase test (Tube method ) 
Procedure: 
         2ml of 3% hydrogen peroxide ( H2O2  ) was taken in a clean test tube and  
few  identical colonies of the test organism were taken from the nutrient agar 
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plate (NAP) with a sterile glass rod or wooden stick and introduced into the test 
tube that contains  H2O2.
(57) 
 
Interpretation : 
 Catalase producing organisms split hydrogen peroxide into water and oxygen 
and produce brisk effervescence due to the release of gaseous oxygen.  
Organisms that were not producing catalase will not produce brisk  
effervescence.   Enterococci were catalase negative. 
 
3.  Bile Esculin Test : 
Procedure:        
         2-3 identical colonies of test organism were taken from the culture plate 
with a sterile inoculating wire or loop and streaked on the surface of the bile 
esculin agar plate.  The plates were incubated  at 35°C for 24-48 hours
(57,49) 
 
Interpretation : 
      Diffuse blackening of the bile esculin  medium or production of black 
coloured haloes around the colonies was considered positive bile esculin test.  
In the presence of 40% bile, esculin, a glycoside ,which is hydrolysed in to 
glucose and esculetine.The esculetine  reacts with ferric ions present in the 
medium to form a black diffusible complex.  Enterococci are bile esculin 
positive. 
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4.  Heat tolerance test : 
Procedure :  
 Test organism from 18-24 hour culture was inoculated into brain heart 
infusion (BHI) broth and incubated at 60°C for 30 minutes in a water bath.   
The broth was subcultured  on to the blood agar plate ( BAP) and MacConkey 
agar plate before heating and after heating. ATCC strain of E.faecalis 29212 is 
used as positive control.
(57) 
 
Interpretation :  
           The ATCC  positive control strain showed growth in the culture plate 
which was steaked both before and after heating the broth at 60°C for 30 
minutes.  If the test organism culture plate shows growth in before and after 
heating were taken as positive heat tolerant  test.  
 
5.Salt tolerance test :   
Procedure : 
           2 to 3  identical colonies from an 18-24 hours old culture of suspected 
enterococcal isolates were inoculated in to the Nutrient broth with 6.5% sodium 
chloride ( 6.5% Nacl ).  The Nutrient broth contains bromocresol purple as the 
Ph indicators. The tubes were incubated  at 35 – 37°C  for 48 hours with  
positive control strain of  Enterococci.
(8) 
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Interpretation : 
               Turbid appearance of the broth with or without a color change from 
purple to yellow is considered as positive reaction. All the enterococcal isolates 
were salt tolerant . 
6.Arginine dihydrolysis Test : Procedure: The isolated enterococcal colonies 
( 2-3 identical) were inoculated in the Moeller‟s decarboxylase broth 
containing arginine and in the control tube containing Moeller‟s decarboxylase 
base broth without arginine. and both the tubes were overlaid with the sterile 
mineral oil. The tubes were incubated at 37°C for four days and were examined 
at 24, 48, 72 and 96 hours.
(47) 
 
Interpretation : 
            Development of deep purple colour  after an initial change of yellow 
colour indicates positive reaction and the persistant yellow colour indicates 
negative reaction. Enterococcus faecalis and Enterococcus faecium were 
arginine dihydrolysis test positive. 
 
7.Mannitol Motility Test :  
Procedure : 
     The mannitol motility medium (MMM) was inoculated with the test 
organism by stabbing with positive and negative control. The tubes were 
incubated at 37°C for 24 hours.The Positive control used was Escherichia coli 
ATCC strain 25922 and negative control used was Staphylococcus aureus 
ATCC  strain25923.
(8)
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Interpretation: 
          Motility of test organism was indicated  by a diffuse  growth extending 
out from the line of inoculation in the Mannitol motility medium (MMM).  Non 
motile organisms  showed growth only at the site of inoculation. In the 
Mannitol motility medium, Mannitol fermenting organisms changed  the colour 
of the medium from red  to yellow due to acid production. Enterococcus 
casseliflavus and Enterococcus gallinorum were mannitol fermenting and 
motile Enterococcus faecalis and Enterococcus faecium were mannitol 
fermenting and nonmotile. 
 
8.Carbohydrate Fermentation test : 
Procedure : 
     The isolated enterococci were inoculated into the carbohydrate fermentation 
media for speciation.  The carbohydrate fermentation media contain 1% 
carbohydrate such as pyruvate, arabinose, sorbitol, sucrose and raffinose in 
separate tubes. The tubes were incubated at 37°C for 24 hours and  
Bromothymol blue is used as ph indicator. 
 
Interpretation : 
        Acid production from carbohydrate was indicated by the colour change 
from blue to yellow. 
 
Antibiogram by Kirby – Bauer disc diffusion method : 
         As per the Clinical laboratory standards Institute (CLSI ) guidelines 
(CLSI document M02&M07) ,the antibiotic susceptibility testing was done by 
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using the Kirby – Bauer disc diffusion method.  Mueller Hinton agar plate  
(MH plate) was used for antibiotic susceptibility testing.  A sterile swab was 
dipped in the 0.5 Mcfarland standard adjusted inoculums. The excess fluid was 
squeezed out and it was streaked on the surface of the agar plate three times, 
turning the  agar plate at 60° each time to produce a lawn culture.  Then 
antibiotic discs were placed within 15 minutes of inoculation in the lawn 
culture.  The inoculated plates were incubated aerobically at 37°C for 16 –
18hours.  Zone size was interpreted  under reflected light except for 
Vancomycin (transmitted light was used). The interpretation as susceptible, 
intermediate and resistant was done as per the CLSI guidelines. 
   Zone size (mm)  S- Sensitive,  I – Intermediate, R – Resistant 
Antimicrobial Drug S(sensitive) I(intermediate R(resistant) 
Ampicillin 10µg ≥17 - ≤16 
Ciprofloxacin 5µg ≥21 16-20 ≤15 
     Doxycycline 30µg ≥16 13-15 ≤12 
Vancomycin 30µg ≥17 15-16 ≤14 
Teicoplanin 30µg ≥14 11-13 ≤10 
High level gentamicin 
(HLG)120µg 
≥10 7-9 ≤6 
High level streptomycin 
           (HLS)300µg 
≥10 7-9 ≤6 
Linezolid 30µg ≥23 21-22 ≤20 
Nitrofurantoin 300µg 
For urine sample 
≥17 15-16 ≤14 
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 Screening test for high level gentamicin resistance (HLGR)
(12,13) 
        The enterococcal isolates were screened for high level resistance to 
gentamicin and streptomycin by using the  high content gentamicin disc (HLG) 
– 120 µg and high content streptomycin  disc(HLS) 300 µg on Mueller Hinton  
agar plate by disc diffusion method as per the guidelines. Bacterial suspension 
equal to 0.5 McFarland standard was used and incubated at 37°C for 16- 18 
hours. The test also included E. faecalis ATCC 29212 as negative control and  
E. faecalis ATCC 51299 as positive control. 
Interpretation :   
 A Zone size of 6 mm is considered Resistant, 7–9 mm considered as 
Inconclusive  and ≥ 10 mm  Susceptible. 
Those  isolated  enterococci that were resistant to High content 
Gentamicin disc (120µg) and those that were inconclusive, they were further 
screened  by the E- TEST ( HLGR).concentration ranges from 0.064µg to 1024 
µg and agar dilution method. 
In the  E- TEST ( HLGR strip HIMEDIA ) , Enterococcal isolates were 
inoculated as for disc diffusion and with the help of forceps the E- test strip 
was placed over the agar surface and incubated aerobically at 35
0
-37
0 
c for 16–
18 hours.Minimum inhibitory concentration (MIC) was determined by the 
point of intersection of the inhibition ellipse with the E-test stip edge.
(58) 
In  agar  dilution method, brain heart infusion (BHI) agar containing 500 
µg/ml of Gentamicin was used for the screening of high level gentamicin 
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resistance (HLGR). In this method Spot inoculation of 10µl of 0.5 McFarland 
standard bacterial suspension was done on to the agar surface along with the E. 
faecalis ATCC 29212 as negative control and  E. faecalis ATCC 51299 as 
positive control. The plates were incubated for 16-18hrs aerobically at 37°C. 
Growth more than 1 colony indicates presumptive high level gentamicin 
resistance (HLGR).
(12,13)
  
 
Molecular characterization of  high level gentamicin resistant (HLGR) 
producing Enterococci by polymerase chain reaction: 
Requirements : 
PureFast® Bacterial DNA minispin purification kit [Kit contains 
Lysozyme, Lysozyme digestion buffer, Proteinase-K, Binding buffer, Wash 
Buffer-1, Wash Buffer-2, Spin columns with collection tube and elution buffer. 
HELINI 2X ReDdye PCR Master Mix, Agarose gel electrophoresis 
consumables and aac-6-le-aph-Ia, aph Ib, aph Ic and aph Id  Primers are from 
HELINI Biomolecules, Chennai, India. 
 
2X Master Mix: 
It contains 2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM 
MgCl2, 1μl of 10mM dNTPs mix and RedDye PCR additives. 
 
Agarose gel electrophoresis: 
Agarose, 50X TAE buffer, 6X gel loading buffer and Ethidium bromide 
are from HELINI Biomolecules, Chennai. 
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PCR: 
HELINI Ready to use aac-(6‟)-le-aph-(2”) Ia gene Primer mix - 
5μl/reaction 
PCR Product size: 500bp 
HELINI Ready to use aph-(2”) Ib gene Primer mix-5μl/reaction 
PCR Product size: 500bp 
HELINI Ready to use aph-(2”) Ic gene Primer mix-5μl/reaction 
PCR Product size: 475bp 
HELINI Ready to use aph-(2”) Id gene Primer mix-5μl/reaction 
PCR Product size: 385bp 
Bacterial DNA Purification 
1ml of overnight culture were centrifuged at 6000rpm for 5min and  
Supernatant  were discarded. Pellet was suspended in 0.2ml PBS. 180μl of 
Lysozyme digestion buffer and 20μl of Lysozyme [10mg/ml]  were added and 
incubated at 37C for 15min. 400μl of Binding buffer, 5μl of internal control 
template and 20μl of Proteinase K were added and mixed well by inverting 
several times. Then this was incubated at 56ºC for 15min.after that  300μl of 
Ethanol were added and mixed well. Then it was transferred  into the 
PureFast® spin column. Centrifuged for 1 min and Discarded the flow-through 
and placed the column back into the same collection tube. 
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500μl Wash buffer-1was added to the PureFast® spin column. 
Centrifuged for 30-60 seconds and discarded the flow-through placed the 
column back into the same collection tube. Then  500μl Wash buffer-2 was 
added to the PureFast® spin column. Centrifuged for 30-60 seconds and 
discarded the flow-through  and  the column back was placed into the same 
collection tube and centrifuged for an additional 1 min. This step was essential 
to avoid residual ethanol. 
The PureFast® spin column was transferred into a fresh 1.5 ml micro-
centrifuge tube and  100μl of Elution Buffer was added to the center of 
PureFast® spin column membrane and Incubated for 1 min at room 
temperature and centrifuged for 2 min.  The column was discarded and  the 
purified DNA was stored  at -20°C. The  Quantity of extracted DNA was 
checked by loading in 1% agarose gel and 5μl of extracted DNA was used for 
PCR amplification. 
PCR Procedure: 
1. Reactions set up as follows; 
         Components Quantity 
                           HELINI RedDye PCR Master mix            10μl 
                          HELINI Ready to use - gene primer mix     5μl 
                          Purified Bacterial DNA                                5μl 
                          Total volume                                               20μl 
2. Mixed gently and spin down briefly. 
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3. Placed into PCR machine and programmed  as follows 
Initial Denaturation: 94ºC for 5 min 
Denaturation:           94ºC for 30sec 
Annealing:                58ºC for 30sec 35 cycles 
Extension:                 72ºC for 30sec 
Final extension:        72º C for 5 min 
 
Agarose gel electrophoresis: 
2% agarose was prepared (2gm agarose in 100ml of 1X TAE buffer and 
melted using microoven) .When the agarose gel temperature was around 60ºC, 
5μl of Ethidium bromide was added. Agarose solution was poured slowly into 
the gel platform and the gel was kept set undisturbed till the agarose solidifies. 
Poured 1XTAE buffer into submarine gel tank. The gel platform was placed 
into the tank. Maintained the tank buffer level 0.5cm above than the gel. PCR 
Samples are loaded after mixed with gel loading dye along with 10μl HELINI 
100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 500bp, 600bp, 700bp, 
800bp, 900bp,1000bp and 1500bp]. Electrophoresis was done at 50V till the 
dye reaches three fourth distance of the gel. Gel was viewed in UV 
Transilluminator and  the bands pattern was observed. 
INTERPRETATION: 
The presence of  aac(6’)-Ie-aph(2”)-Ia gene was indicated by the 
amplification of  500 bp PCR product. 
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The presence of aph(2”)-Ib gene was indicated by the amplification of 
500 bp PCR product . 
The presence of  aph(2”)-Ic gene was indicated by the amplification of  
475 bp PCR product.  
The presence of aph(2”)-Id gene was indicated by the amplification of 
385 bp PCR product . 
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RESULTS 
 
          Urine, blood, pus and wound swab specimen were collected from 396 
patients who were admitted at Govt. Rajaji Hospital.  Both sexes of all age 
groups were included.  Among 396 specimen, 368 showed growth and 28 
specimen showed no growth. Out of 396 samples, 159 were from urine, 103 
were from pus, 74 were from blood  and 60 were from wound swab.  Among 
368 samples, 104 were enterococci, 121 were other gram positive cocci and 
143 were gram negative bacilli. 
 
Table -I and Chart I :  Specimen wise distribution cases ( n=396 ) 
Site Number of specimen 
Urine 159 (40.15%) 
Pus 103 (26.01%) 
Blood 74 (18.6%) 
Wound swab 60 (15.15%) 
 
 
159 
103 
74 
60 
0
20
40
60
80
100
120
140
160
180
urine pus blood wound swab
total specimen (n= 396) 
total specimen 396
58 
 
 Table I and Chart I shows out of 396 samples 159 (40.15%) were 
urine,103(26.01%) from pus, 74(18.6%) from blood and 60(15.15%) from 
wound swab.It was found maximum number of samples were from 
urine(40.15%). 
Table II and Chart II:  GROWTH Vs NO GROWTH FROM SPECIMEN: 
Total specimen Showed growth Showed no growth 
396 368 (92.29%) 28 (7.07%) 
 
 
 
  From the table II &Chart II, out of 396 samples, 368 (92.29%) 
showed growth and 28(7.07%) showed no growth. 
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Table III & Chart III:  Specimen wise isolation of Organisms  (n=368) 
SPECIMEN ENTEROCOCCI OTHER GPC GNB TOTAL 
URINE 48(31.57%) 26(17.1%) 78(51.3%) 152 
sPUS 30(30.3%) 42((42.42%) 27(27.27%) 99 
BLOOD 10(16.9%) 28(47.45%) 21(35.59%) 59 
WOUND 
SWAB 
16(27.53%) 25(43.1%) 17(29.31%) 58 
TOTAL 104((28.2%) 121(32.88%) 143(38.85%) 368 
 
Chart III :   Specimen wise isolation of Organisms  (n=368) 
 
 From the Table III Chart III, it was found that,  Out of 152 urine 
specimen which showed growth, 48 (31.57%)  were enterococci, 26 (17.1%) 
were other gram positive cocci and 78 (51.3%) were gram negative bacilli. 
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Out of 59 blood specimen which showed growth, 10(16.9%) were 
enterococci, 28(47.45%) were other gram positive cocci,21( 35.59%) were 
gram negative bacilli. 
Out of 99 pus specimen which showed growth, 30 (30.3%) were                  
enterococci, 42 (42.42%) were other gram positive cocci, and 27 (27.27%) 
were gram negative bacilli. 
Out of 58 wound swab specimen which showed growth, 16 (27.53%)  
were enterococci, 25 (43.1%) were other gram positive cocci and 7 ( 29.3%) 
were gram negative bacilli. 
               Out of  total 368 specimen showed growth, 104(28.26%)  were 
enterococci,121(32.88%) were other gram positive cocci, 143 ( 38.85%) were 
gram negative bacilli. 
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Table IV : Specimen wise isolation of Enterococci ( n=104) 
SPECIMEN 
NO OF ENTROCOCCAL 
ISOLATES 
PERCENTAGE 
URINE 48 46.15% 
PUS 30 28.84% 
WOUND SWAB 16 15.38% 
BLOOD 10 9.6% 
  
Chart  IV : Specimen wise isolation of Enterococci ( n=104) 
 
             From the Table IV & Chart IV, it was found that, Out of 104 
enterococcal isolates from various samples, 48(46.15%) were isolated from 
urine samples, 10 (9.6%) from blood samples,30(28.84%)from pus samples 
and 16(15.38%) from wound swab samples.  From the above table, it was 
observed that Enterococci were isolated more from urine sample (46.15%) 
followed by pus sample (28.84%). 
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 Table V :   Age wise distribution of Enterococcal isolates (n=104) 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
< 1 2 1.92% 
1 -12 18 17.3% 
13 – 45 38 36.53% 
46 – 60 24 23% 
   >60 22 21.15% 
  
Chart V :   Age wise distribution of Enterococcal isolates (n=104) 
 
           From the Table V & Chart V, it was found that the analysis of age wise 
distribution of  isolated Enterococcal species from various clinical specimen 
showed predominance of enterococcal infection in the age group of 13-45yrs 
that is  38 cases (36.53%). 
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Table  VI : Sex wise  and adult -children distribution among Enterococcal 
species (n= 104)                       
 ADULT CHILDREN TOTAL 
MALE 51 15 66(63.46%) 
FEMALE 33 5 38(36.53%) 
TOTAL 84(80.76%) 20(19.2%) 104 
 
Chart  VI :  Sex wise  and adult -children distributionamong Enterococcal 
species (n= 104)                      
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           From the Table VI & Chart VI, it was found that,  Out of 104 
enterococcal isolates, 66 (63.43%) were isolated from male patients and 
38(36.53%) were isolated from female patients. Out of 104 enterococcal 
isolates  84 (80.76%) of adults and 20 (19.23%) of children were affected by  
Enterococcal infection. 
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Table VII :Distribution of Enterococcal species among the specimen  
SPECIMEN E.faecalis E.faecium TOTAL 
URINE 37 (77.1%) 11 (22.9%) 48 
PUS 21 (70%) 9 (30%) 30 
WOUNDSWAB 12 (75%) 4 (25%) 16 
BLOOD 7 (70%) 3 (30%) 10 
TOTAL 77 (74.03%) 27 (25.96%) 104 
 
Chart VII : Distribution of Enterococcal species among the  specimen  
 
 From the Table VII & Chart VII, it was found that,  In the urine samples 
,out of 48 enterococcal isolates 37 (77%) were E.faecalis,11 (22.9%) were 
E.faecium.  In the pus samples ,out of 30 enterococcal isolates 21(70%) were 
E.faecalis, 9(30%) were E.faecium.  In the blood samples ,out of 10 
enterococcal isolates 7(70%) were E.faecalis, 3(30.%) were E.faecium    In the 
wound swab samples ,out of 16 enterococcal isolates 12 (75%) were E.faecalis 
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4 (25%) were E.faecium..No other enterococcal species were isolated from the 
various specimen collected during the study period 
Table VIII : Species wise distribution of isolated Enterococci (n=104) 
Species Number 
E.faecalis 77(74.03%) 
E.faecium 27(25.96%) 
 
Chart VIII: Species wise distribution of isolated Enterococci (n=104) 
 
 From the TableVIII &ChartVIII, it was found that, E.faecalis 77 ( 
74.03%) was the predominant species followed by E.faecium, 27 (25.96%).                      
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Table IX: Antibiotic susceptibility pattern of Enterococcus species by Kirby Bauer disc diffusion method 
E
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A
T
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S
 PEN AMPI CIP DOXY HLS HLG TEICO VANCO LINE 
S R S R S R S R S R S R S R S R S R 
E.faecalis 77 
56 
72.7% 
21 
27.2% 
57 
74% 
20 
25.9% 
53 
68.8% 
24 
31.1% 
30 
38.9% 
47 
61.1% 
57 
74.0% 
20 
25.9% 
29 
37.6% 
48 
62.3% 
75 
97.4% 
2 
2.6% 
73 
94.8% 
4 
5.19% 
75 
97.4% 
2 
2.6% 
E.faecium 27 
17 
62.9% 
10 
37.0% 
19 
70.0% 
8 
29.6% 
17 
62.9% 
10 
37.0% 
11 
40.7% 
16 
59.25% 
19 
70.3% 
8 
29.6% 
9 
33.3% 
18 
66.6% 
25 
92.6% 
2 
7.4% 
23 
85.18% 
4 
14.8% 
25 
92.5% 
2 
7.5% 
 
Antibiotic susceptibility pattern of isolated Enterococcus species from the various clinical specimen . 
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Chart IX a & b : Antibiotic susceptibility pattern of Enterococcus species 
by Kirby Bauer disc diffusion method Chart IX (a): 
 
Chart IX ( b) 
 
 From the Table IX & Chart IX a & b, it was found that, most of the E. 
faecalis were sensitive to ampicillin (74%), teicoplanin (97.4%) and 
vancomycin (94.8%).  They were resistant to ciprofloxacin (31.1%) and 
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doxycycline (61%).  Among the 77 isolated E .faecalis 48 (62.3%) were high 
level gentamicin resistant and 20 (25.9%) were resistant to high level 
streptomycin.  
 Among the 27 isolates of E .faecium, resistance pattern of various 
antimicrobial agents were as follows ampicillin 8 (29.6%), ciprofloxacin 
10(37%), doxycycline 16(59.25%) , high level gentamicin resistance 
18(66.6%) and to high level streptomycin resistance 8(29.6%). But E.faecium 
are sensitive to  teicoplanin 25(92.6%) and vancomycin 23 (85.18%).   
E.faecium showed more antimicrobial resistance pattern than E.faecalis.  
Vancomycin  resistance  among  the  isolated E.faecalis and  E.faecium were 
5.19% & 14.8% respectively.  
High level gentamicin resistance among the isolated 104 Enterococcal 
speciecies were 66 ( E .faecalis -48, E .faecium,-18) 63.46%. High level 
streptomycin resistance among the isolated 104 Enterococcal speciecies were 
(E.faecalis-20,E .faecium,-8)26.9%. 62.3% of E .faecalis and 66.6% of  
E.faecium were high level gentamicin resistant. 
Among the vancomycin resistant E.faecalis isolates that is out of 4, three 
isolates showed HLGR and 1 showed both HLGR and HLSR.Among the 
vancomycin resistant E.faecium that is out of 4, all showed HLGR and 2 
showed HLSR and both HLGR & HLSR are 2. All the high level gentamicin 
resistant isolates were sensitive to teicoplanin and linezolid. 
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Table X : High level aminoglycoside resistance (HLAR) among E. faecalis 
and E. faecium isolates by disc diffusion method. 
ENTEROCOCCAL 
SPECIES 
TOTAL  
ISOLATES 
RESISTANCE 
TO BOTH 
HLS &  
HLG 
RESISTANCE 
TO HLS 
RESISTANCE 
TO HLG 
E.faecalis 77 16 (20.7%) 20(25.97%) 48(62.33%) 
E.faecium 27 8 (29.6%) 8(29.6%) 18(66.66%) 
TOTAL 104 24(23.07%) 28(26.9%) 66(63.46%) 
 
Chart X (a) : High level aminoglycoside resistance (HLAR) among the 
isolated enterococcal  species by disc diffusion method. 
 
 From the table X & Chart X (a) Out of total 104 enterococcal isolates, 
66(63.46%) were HLGR, 28(26.9%) were HLSR and 24(23.07%) were 
resistant to both HLG and HLS. 
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 Chart X (b) : High level aminoglycoside resistance (HLAR) among E. 
faecalis and E. faecium isolates by disc diffusion method. 
 
From the Table X & Chart X (b) it was found that, Among the isolated  
77  E.faecalis, 48(62.33%) were HLGR, 20(25.97%) were HLSR and both 
HLGR &HLSR were 16(20.77%). 
Among the isolated 27 E.faecium, 18(66.6%) were HLGR, 8(29.6%) 
were HLSR and both HLGR &HLSR were 8(29.6%). 
Comparision of E-Test and agar dilution method for detecting high level 
gentamicin resistance in enterococci: 
66 High level gentamicin resistance (HLGR) Enterococcal isolates 
(E.faecalis -48, E.faecium -18), were subjected to E-test and agar dilution 
method for screening HLGR > 500µg/ml   and the results were as follows 
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Table XI : Comparision of E-Test and agar dilution method for detecting 
high level gentamicin resistance in enterococci: 
No. enterococcal isolate 
subjected for testing 
MIC >500µg/ml of gentamicin 
by E-test by agar dilution method 
66 66 66 
 
From the Table XI  it was found that, in the E-test all the High level 
gentamicin resistance isolates that were screened by the high content 
gentamicin disc (120µg) showed MIC >1024 µg/ml. In agar dilution screening 
method by using Brain Heart Infusion agar containing gentamicin 500 µg/ml, 
showed growth in all the 66 enterococcal isolate. 
 
Prevalence of genes responsible for HLGR : 
  Among the total 104 enterococcal isolates, 66(63.46%) were High level 
gentamicin resistant(HLGR) which was subjected to the  molecular 
characterization study showed  the results as follows 
Table XII :Prevalence of genes responsible for HLGR 
Name of the HLGR gene E.faecalis (n=48) E.faecium (n=18) 
aac(6)-Ie-aph(2)-Ia 48 18 
(aph(2)-Ib _ _ 
aph(2)-Ic _ _ 
aph(2)-Id _ _ 
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 From the table XII , it was found that,  all the isolated enterococci 
(n=66) that are  HLGR by screening test posses the gene that codes the 
bifuntional enzyme aac(6‟)-Ie-aph(2”)-Ia. 
 Other genes that are responsible for high level gentamicin (aph(2”)-Ib, 
aph(2”)-Ic & aph(2”)-Id ) were  not detected in this study. 
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DISCUSSION 
 
 Enterococci species have emerged as an important cause of health care 
acquired infections.Urinary tract infections,intra abdominal and pelvic 
infections,bloodstream infection are commonly encountered  hospital acquired 
infections  by these enterococcal species. Enterococci also cause  surgical site 
infections, endocarditis, neonatal sepsis and meningitis.  The major reason for 
existence of these organisms in hospital environment is due to the intrinsic 
resistance to commonly used antibiotics. Enterococci have the ability to acquire 
resistance mechanism to various  antibiotics either by means of gene transfer by 
plasmids and transposons or by means of mutation. Serious  enterococcal 
infections like endocarditis, meningitis and sepsis are usually treated with 
combination of two antibiotics that is one acts on cell wall synthesis like beta 
lactam or glycopeptides (pencillin,ampicillin or vancomycin and an 
aminoglycoside which inhibits  bacterial protein synthesis(i.e gentamicin or 
streptomycin).The addition of cell wall acting agent,such as ampicillin or 
vancomycin,  increases uptake of the aminoglycoside in to the cell,which results 
in synergistic  bactericidal effect on  enterococcus.If  Enterococci have acquired 
gentamicin  resistant genes (HLGR) that mediate production of aminoglycoside 
modifying enzymes, results in loss of synergism between cell wall acting agents 
and gentamicin.  
 Inherent resistance to the commonly used antibiotics makes these 
organism excellent survivors in health care places and cause health care  
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acquired infections. In this  study, prevalence of high level gentamycin 
resistance among the isolated  enterococcal species in the various clinical 
sample and molecular characterization of genes  that are responsible for high 
level gentamycin (MIC>500µg/ml ) resistance have been assessed. 
             In this present study, out of 396 samples processed, 368 showed 
growth and 28 were no growth. Out of this 368 isolates, 104 (28.26%) were 
Enterococcal species, 121 (32.88%) were other gram positive cocci and 
143(38.85%)  were gram negative bacilli. 
            In the present study, among 104 isolated Enterococcal species, 48 
(46.15%) were from urine, 10 (9.6%%) from blood, 30 (28.8%) from pus and 
16 (15.3%) from wound swab samples which was in concordant with the study  
by Baragundi MC et al
(5)
 who observed that, out of 120 enterococcal isolates, 
50(41.66%) were isolated from Urine sample, 35(29.1%)  from blood sample, 
20(16.66%) from pus sample and 15(12.5%) from wound swab samples. 
.
In 
both these studies showed that,  Enterococci were commonly isolated more 
from urine samples,which was similar to the study by  Reza Faraji1
(85)
,  
Leblank et al
(52)
(36.6%). The observation in the present study was more 
number of isolation of enterococcal species from the urine sample due to the 
normal residence of enterococci in the genitourinary tract. 
 In the present study, Enterococcal species were isolated from 13-45 
years (36.53%) of age followed by 46-60 years (23%). Most of the 
enterococcal infections were associated with males 66(63.4%) than females 
38(36.5%).  According to Kayoko Hayakasswa et al
(45)
 , mean age of the 
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enterococcal infection study population  was in the range of 45-60 years,and 
also stated that most of the affected people in their study were male (53.6%). 
Analysis of adult-children distribution showed incidence of Enterococcal 
infections were more common in adults 84(80.76%) than children 20 (19.23%). 
In the present study, among the 104 isolated enterococcal species, 77 
(74.03%) were E.faecalis, 27(25.96%) were E. faecium. .No other enterococcal 
species isolated during the study period. This correlates with study done by  
Sreeja et al
(94) 
(E.faecalis 76%,E.faecium 24%), Emaneini et al
(63)
 E.faecalis 
(70.3%), E.faecium (29.7%), Lathika et al
(51)
 (E.faecalis 75%, E.faecium23%), 
Sivasankari et al
(92) 
(E.faecalis (78.8%), E.faecium (21.2%), Reza Faraji
(85)
, 
E.faecalis (72.4%), E.faecium (13.79%) Mohammad Mehdi Soltan et al
(69)
 
E.faecalis (70.%), E.faecium (30%), in contrast to the study by Niharika et 
al
(71) 
(E.faecalis 51.4%,E.faecium 48.6%), Chandrim et al
(17)
 (E.faecalis 
46.9%, E.faecium 33.3%), Haiying et al
(35)
 E.faecalis (28.2%), E.faecium 
(53.8%). 
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Comparative findings from various studies : 
Study by E.faecalis E.faecium 
In the present study 74.03% 25.96% 
Sreeja et al 76% 24% 
Emaneini et al 70.3% 29.7% 
Lathika et al       75% 23% 
Sivasankari et al 78.8% 21.2% 
Reza Faraji1, 72.4% 13.79% 
Mohammad Mehdi 
Soltan Dallal et al 
70% 30% 
Niharika et al 51.4% 48.6% 
Chandrim et al 46,9% 33.3% 
Haiying et al 28.2% 53.8% 
 
With  respect to  isolation of various species of enterococci ,E.faecalis 
&E.faecium  were only  isolated in the present study which was in accordant to 
the study conducted by Sreeja et al
(94)
, Emaneini et al 
(65)
& Sivasankari et 
al
(92)
 and in contrast to the study by Reza Faraji1
(85)
,  (E.faecalis , E.feacium , 
E. hirea, E avium, E. gallinarium , and E. mundtii) ,Schouten et al 
(95)
(E.faecalis , E.feacium , E. hirea, E durans, E. gallinarium , and 
E.casseliflavus). MM Salem Bekhit et al
(64)
  (E.faecalis , E.feacium , E. hirea,  
E. gallinarium , and E.casseliflavus). 
Most of the studies mentioned above and also in the present study 
E.faecalis was the predominant species isolated among Enterococcus. It was 
noted in this study and others mentioned above,there was increasing trend in 
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the prevalence of  E.faecium in the clinical settings. (Previously E.faecalis to 
E.faecium ratio was 10:1). 
In this study  the E. faecalis and E. feacium  were the most prevalent 
species isolated . The  reasons for this are, these species are normal flora of the 
alimentary tract, vagina,and  mouth while other species are mostly found in the 
environment and  also their   ability to acquire resistance to various 
antimicrobial drugs and possesing  more variable virulent factors when  
compared to the other enterococcal species.  
 Among the total 104 enterococcal isolates,,66(63.46%) were HLGR, 
29(27.8%) were HLSR and 24(23.07%) were resistant to both HLG and HLS. 
According to  the study by Sivasankari et al
(92)
, Martha L. Sanchez et al 
(58)
& Elango padmasini et al
(23)
, HLGR & HLSR  were 50%&38.4% 
,31%&42% and 42.7%,&29.8% respectively. 
 
HLGR & HLSR AMONG ENTEROCOCCAL SPECIES : 
Study by HLGR HLSR 
In the present study 63.46% 27.8% 
Sivasankari et al 50% 38.4% 
Martha L. Sanchez et al 31% 42% 
Elango padmasini et al 42.7% 29.8% 
 
 In the present study, among the isolated 104 enterococcal species high 
level gentamicin resistance (HLGR) were 66(63.46%) ,29 (27.88%) were high 
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level streptomycin resistance (HLSR) and 24(23.07) were both HLGR 
&HLSR. The reason for higher  high level gentamicin resistance (HLGR) than  
high level streptomycin  resistance (HLGR)  could be due to restricted 
indication for usage of streptomycin.( like  in  tuberculosis treatment etc, )                    
 In the present study, among the isolated 77 E.faecalis, 48(62.33%) were 
high level gentamicin resistance(HLGR) which was concordant with Mithra et 
al
(61)
, Sarika et al
(87)
 ,Randhawa et al
(83)
 & Mohammad Mehdi Soltan Dallal 
et al
(69)
 where it was 67.2%, 60% , 68%  and 61.5% respectively but lower in  
the study conducted  by Maoddab et al
(62)
, Sivasankari et al
(92)
, C. Fernandes 
et al 2011
(26)
,it was13%.,48.7%&53.5% respectively.The presence of high 
level gentamicin resistance (HLGR) is predictive of loss of synergy between 
cell wall acting agents such as vancomycin or ampicillin and gentamicin 
.(Murray et al,1998) 
HLGR AMONG E. faecalis : 
Study by HLGR in E.Faecalis (%) 
In the present study 62.33% 
Mithra et al 67.2% 
Sarika et al 60% 
Randhawa et al 68% 
Mohammad Mehdi Soltan  
Dallal et al 
61.5% 
 Among the isolated  77 E.faecalis, 20(25.97%) were high level 
streptomycin resistance (HLSR) which was comparable to the study by 
Haiying et al
(35)
 & Mithra et al 
(61)
27.4% & 22.7% respectively, but it was 
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higher in the study conducted  by Niharika et al
(71)
 and Martha L Sanchez
(58)
, 
it was 60.7% &42% respectively. 
HLSR AMONG E.FAECALIS : 
Study by HLSR in E.Faecalis (%) 
In the present 25.97% 
Haiying et al 27.4% 
Mithra et al 22.7% 
Niharika et al 60.7% 
Mohammad Mehdi Soltan Dallal et al 42% 
 
 Among the isolated 77E.faecalis. both high level gentamicin resistance 
(HLGR) & high level streptomycin resistance(HLSR) were 16(20.77%) which 
was concordant with the study done by Verma et al
(100)
 ,it was 30.4%,but not 
with the study by  Sarika et al
(87)
, Gulcin et al
(30)
, Randhawa et al
(83)
  & 
Niharika et al
(71)
 where it was 54%, 36% 43% & 49.2% respectively. 
BOTH HLGR & HLSR AMONG E. FAECALIS : 
Study by Both HLGR & HLSR in E.Faecalis (%) 
In the present 20.77% 
Verma et al 30.4% 
Sarika et al 54% 
Niharika et al 49.2% 
Gulcin et al 36% 
Randhawa et al 43% 
 
                In the present study,among the isolated 27 E.faecium, 18(66.6%) 
were high level gentamicin resistance( HLGR) which was in concordant with 
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the study conducted by Sivasankari S et al
(92)
,Sanal C. Fernandes et al 
2013
(26)
 & Mohammad Mehdi Soltan Dallal et al 
(69) 
54.6% ,53% &79% 
respectively ,but it  was higher than the study conducted  by Mithra et al
(61)
, 
Lathika et al
(51)
, Carol et al
(15)
 & Gulcin et al
(30)
 it was 32.8%, 40% ,32.6%  
& 48% respectively.  
HLGR AMONG E. FAECIUM : 
Study by HLGR in E.faecium (%) 
In the present 66.6% 
Sivasankari S et al 54.6% 
Sanal C. Fernandes et al 53% 
Mohammad Mehdi et al 79% 
Mithra et al 32.8% 
Lathika et al 40% 
Carol et al 32.6% 
Gulcin et al 48% 
 
                   Among the isolated 27 E.faecium ,9 (33.3%) were high level 
streptomycin resistance (HLSR)  but it was low in the study done by Maoddab 
et al
(62)
& Niharika et al
(71)
, it was 15% & 8.9% respectively and high in the 
study by  Sivasankari S et al
92)
, Sanal C. Fernandes et al 2013
(26)
where they 
reported 54.8% & 58.8%  respectively. 
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HLSR AMONG E.FAECIUM : 
Study by HLSR in E.Faecium(%) 
In the present 33.3% 
Maoddab et al 15% 
Niharika et al 8.9% 
Sivasankari S et al 54.8% 
Sanal C. Fernandes et al 58.8% 
 
Out of 27 E.faecium,  both high level gentamicin resistance (HLGR) & 
high level streptomycin resistance (HLSR) were 8(29.6%).  
 In the present study  high level gentamicin resistance (HLGR) among 
isolated enterococci were higher than the most of studies  done all over 
india.The reason could be that our hospital is tertiary care level and usage of 
antibiotics are more, presence of intensive care units ( medical,surgical 
paediatric etc),prolonged hospital stay for chronic disease. 
 In the present study high level gentamicin resistance (HLGR) was found 
higher in E .faecium  than E.faecalis which  was concordant  to the study done 
by Gordon et al
(33)
 and Mendiratta et al
(21)
. 
 In this present study, out of 104 enterococcal isolates, 8 (7.69%) were 
vancomycin resistant. The prevalence of VRE in this study was 7.69% which 
was in par with the results shown by Baragundi et al
(5)
, where they reported 
7.5% of vancomycin resistant enterococci (VRE). and was lower than the study 
of Karmarker MG et al
(44)
, it was 23% . 
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 In the present study, antimicrobial susceptibility results of E. faecium 
showed 70.4%% and E. faecalis showed 16.9% ampicillin resistance which 
was in concordant with a study conducted by Salem-Bekhit etal2012
(64)
 and 
Sivasankari.S et al
(92)
where they reported 70.4%,15.7% and 72.7%,24.3% 
respectively. Agarwal J et al
(1)
 have reported significantly higher resistance to 
ampicillin among  E. faecium isolates which was similar to our study and also 
they documented multiple drug resistant enterococci which was a similar 
finding in the present study.in the present study it was found all  HLGR 
enterococcal isolates were sensitive to linezolid & teicoplanin. 
 In the present study out of 104 enterococcal isolates 63.4% were high 
level gentamicin resistance (HLGR), where in the study conducted  by Haiying 
Niu et al,
(35)
Dr.Narayan Shrihari et al
(22)
 they reported lower rate 
42.7%.,44.2% respectively.  In this present study out of 104 enterococcal 
isolates 26.9% were high level streptomycin resistance (HLGR), where in the 
study conducted  by Haiying Niu etal
(35)
,Dr.Narayan Shrihari etal
(22)
 they 
reported lower rate 42.7%.,44.2%. 
 In the present study all  high level gentamicin resistance (HLGR) 
enterococcal isolates screened by high content disc (gentamicin 120 µg) ,were 
also showed  Minimum inhibitory concentration >500µg/ml by E-test method 
and agar dilution method. This finding was also observed in the study 
conducted by Martha L.Sanchez et al
(58)
 .According to CLSI guidelines 
screening method for high level gentamicin resistance (HLGR) are disc 
diffusion method with high content gentamicin disc (120 µg), agar dilution 
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method and broth dilution method. But in this study and study by Martha 
L.Sanchez et al
(58)
  showed that the usefulness of E-test to predict high level 
gentamicin resistance (HLGR) among enterococci.This has to be evaluated by 
further studies.  
In the present study all  high level gentamicin resistance (HLGR) 
enterococcal isolates( n=66) were submitted for polymerase chain reaction for 
molecular characterization of the genes responsible for high level gentamicin 
resistance (HLGR). Result showed out of four genes i.e (aac(6’)-Ie-aph(2”)-Ia, 
aph(2”)-Ib,  aph(2”)-Ic, aph(2”)-Id ) that determine  high level gentamicin 
resistance (HLGR) in enterococci, the bifunctional gene aac(6’)-Ie-aph(2”)-Ia, 
was alone detected .Other genes were not detected which was concordant with 
the study done by Elango Padmasini et al
(23)
 & Mohammad Mehdi Soltan 
Dallal et al
69)
 in which they detected aac(6‟)-Ie-aph(2”)-Ia, only, other genes  
were not detected in their enterococcal isolates. 
According to the study done by Haiying Niu et al 
(35)
, they reported the 
prevalence of high level gentamicin resistance (HLGR) genes among 
enterococci were as follows, aac(6‟)-Ie-aph(2”)-Ia(89.3%),  aph(2”)-Ib(0%) 
,aph(2”)-Ic(7.1%) aph(2”)-Id(10.7%) . 
According to Joseph W Chow et al 
(39) 
(clinical infectious Diseases 
2000; 31:586-9),  the prevalence of high level gentamicin resistance (HLGR) 
genes among enterococci were as follows, aac(6‟)-Ie-aph(2”)-Ia(79%), aph 
(2”)-Ib(5%), aph(2”)-Ic(1.6%), aph(2”)-Id (14.%). According to Mithra Khani  
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et al
(58)
,   the prevalence were  aac(6‟)-Ie-aph(2”)-Ia(61.6%), other genes not 
evaluated in this study. 
According to the the study done by  M.Emaneini B.Khoramian, et al 
(65) 
the prevalence of high level gentamicin resistance gene was aac(6‟)-Ie-
aph(2”)-Ia,  that was found in 96.2% (26/27) of the isolates. 
In the present study and other studies it was concluded that the most 
prevalent gene that  is responsible for high level gentamicin resistance (HLGR) 
among enterococcal species is aac(6’)-Ie-aph(2”)-Ia. 
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SUMMARY 
 
 A total of 396 samples were collected to study the High level 
gentamicin resistance and its molecular characterization in 
Enterococcal isolates. 
 A total of about 104 Enterococcal strains were isolated from clinical 
specimens.  Majority of the Enterococcal isolates were from urine 
46.15% followed by pus 28.84%, wound swab 15.38% and blood 
9.6%. 
  Isolation of Enterococci were more in adults 84(80.76%) than in the  
children 20 (19.23%) and also more in male patients 66(63.46%) 
when compared to female patients 38 (36.53%). 
  E. faecalis was the predominant species isolated in the present study,  
with an isolation rate of about 77/104(74.03%), followed by E. 
faecium 27/104(25.96%). Other species of enterococci were not 
isolated and with the highest isolation rate of  E. faecalis & E. 
faecium was  in the urine samples. 
  High level gentamicin resistance were seen in 63.4% of Enterococcal 
isolates by disc diffusion method and similar results were also seen in 
E-test method & agar dilution method. 
 In antibiotic susceptibility testing(AST), E.faecium showed the 
following resistant pattern, penicillin (37%), ampicillin (29.6%), 
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ciprofloxacin (37%) doxycycline (59%), High level gentamicin 
(66.6%), high level streptomycin (29.6%), teicoplanin (7.4%),  
vancomycin (14.8%). 
 In antibiotic susceptibility testing (AST), E.faecalis showed the 
following resistant pattern, penicillin (27.2%), ampicillin (16.8%), 
ciprofloxacin (31%), doxycycline (61%), high level gentamicin 
(62.3%), high level streptomycin (25.9%), teicoplanin (2.6%), 
Vancomycin (5.19%%). 
   Resistance to both high level streptomycin (HLSR) and high level 
gentamicin (HLGR) were observed in 23.07% of isolates. The high 
level gentamicin resistance was higher in E. faecium 18/27 (66.6%)  
than in E. faecalis  62.3% (48/77). 
 All the HLGR enterococcal isolates were sensitive to teicoplanin and 
linezolid. 
 All the 66  high level gentamicin resistance isolates (E. faecalis-48 
and E. faecium-18) were subjected to Polymerase Chain Reaction for 
the detection of resistance determining genes aac(6’)-Ie-aph(2”)-Ia ,  
aph(2”)-Ib,  aph(2”)-Ic,  aph(2”)-Id. 
 In PCR assay, out of four genes, the gene aac(6’)-Ie-aph (2”)-Ia was 
alone detected in all the isolates. This gene codes the bifuntional 
aminoglycoside modifying enzyme which confers resistant to all the  
commonly used aminoglycosides except streptomycin.  
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 The present study showed the aac(6’)-Ie-aph(2”)-Ia gene was the 
most prevalent  gene present in Enterococci which was similar  in 
other studies. 
 Routine testing for HLGR Enterococci is necessary to reduce the long 
stay of the patient and transmission of resistant Enterococci to other 
patients. 
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CONCLUSION 
 
 Enterococci are one among the common bacterial organisms causing  
serious health care associated infections at Govt.Rajaji Hospital 
(GRH), Madurai Medical College Madurai. 
 Among 104 Enterococcal  isolates from various specimen, E.faecalis 
77 (74.03%) and E.faecium 27(25.96%) were isolated. 
 Most of isolated enterococci were sensitive to  teicoplanin and 
linezolid.( S >90%) 
 High level gentamicin resistance were seen in 63.4% of Enterococcal 
isolates by disc diffusion method and similar results were also seen in 
E-test method & agar dilution method. 
 High level gentamicin resistance in E.faecalis and E.faecium were 
62.33% & 66.66% respectively. 
 Vancomycin resistance in E.faecalis and E.faecium were 5.19%% & 
14.8% respectively. 
 All  the  High level gentamicin resistance  enterococcal isolates were 
sensitive to teicoplanin(100%) and linezolid.(100%) 
 In PCR assay, out of four genes, the gene aac(6’)-Ie-aph(2”)-Ia was 
alone detected in all the isolates. This gene codes the bifuntional 
aminoglycoside modifying enzyme which confers resistant to all the  
commonly used aminoglycosides except streptomycin resulting in 
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loss of synergism between cell wall acting drugs and 
aminoglycosides except streptomycin. 
 The higher prevalence of High level gentamicin resistant enterococci 
have posed serious problem in the management serious enterococcal 
infection where aminoglycosides (gentamicin or streptomycin ) is 
indicated along with the cell wall acting agents, thus limiting the 
therapeutic options. 
 Judicious use of aminoglycosides, and regular surveillance of all 
Enterococcal isolates for High level gentamicin resistance is 
necessary for the prevention of nosocomial transmission of  resistant 
strain. 
 Appropriate surveillance, stringent infection control practice and 
hospital infection control committee guidance is very important to 
control the spread  of  High level gentamicin resistant  Enterococci. 
 
 
 
 
 
           
 
ANNEXURE-1 
 
PREPARATION OF GRAM STAIN: 
GRAM STAIN REAGENTS 
1. Methyl violet – Primary stain 
Methyl violet 10g 
95% ethyl alcohol 100ml. 
Distilled water 1L 
2. Gram’s lodine – Mordant 
lodine 10g 
Potassium lodide 20g 
Distilled water 1 L 
3. Acetone – Decolouriser 
4. Dilute CarbolFushsin – Counter stain 
Basic fushsin 0.3 g 
95% Ethyl alcohol 10 ml 
Phenol crystals, melted 5 ml 
Distilled water 95 ml 
 
 Basic fuchsin was dissolved in alcohol 5% phenol solution was added 
and was allowed to stand overnight. Then the solution filtered through coarse 
filter paper. 
 
ANNEXURE-2 
PREPARATION OF MEDIA 
PREPARATION OF NUTRIENT AGAR 
Contents: 
 Peptone  – 5 g 
 Beef extract  –1.5 g 
 Yeast  extract  –1.5 g 
 Sodium choloride – 5 g 
 Agar   – 15g 
28 g of the contents were suspended in 1000 ml of distilled water. It was 
heated to boiling to dispense the medium completely. Medium was sterilized by 
autoclaving at 121 degree C at 15 lbs pressure for 15 minutes. 
PREPARATION OF BLOOD AGAR 
Nutrient agar 100 ml 
Sheep blood (defibrinated) 10 ml 
 The sterile nutrient agar was melted by steaming and cooled to 45 deg C 
 5%-10% sheep blood was added aseptically with constant shaking. 
 The blood was mixed with molten nutrient agar thoroughly but gently, to 
avoid froth formation. To remove the bubbles, media was flamed. 
 Immediately poured into petri dishes and allowed to set. 
 
PREPARATION OF MUELLER – HINTON AGAR Contents: 
Beef extract 2.0 gm 
Acidicase peptone 17.5 gm 
Starch 1.5 gm 
Agar 17.0 gm 
Distilled water 1000 ml 
Final pH 7.4+0.2 
 
Dissolved the ingredients in one liter of distilled water.Mixed thoroughly. 
Heated with frequent agitation and boiled for one minute. Dispensed and sterilized by 
autoclaving at 121  deg.  C for 15 minutes.Should not be overheated.When remelting 
the sterile medium, heated as briefly as possible. 
 
 
 
 
 
 
 
 
 
 
CONSENT FORM 
 
Nehahspapd; ngah;: ___________ taJ: _______ ,dk;: _______________ 
tpyhrk;: ________________________________________________________ 
jfty; mspf;fg;gl;lxg;Gjy; gbtk; 
 Nkw;Fwpg;gpl;lkUj;JtMa;tpy; Xh; gq;Nfw;ghsuhfNrh;f;fg;gl;l 
,jd; %yk; ehd; Rje;jpukhfvd; xg;Gjiymspf;fpNwd;. 
,e;jkUj;JtMa;tpd; Nehf;fk; kw;Wk; Kf;fpaj;Jtk; gw;wpkw;Wk; 
mjdhy; Vw;gLk; vdJ nghWg;Gfs; gw;wp vdf;F jfty; 
njhptpf;fpd;whh;. ,NjhL $Ljyhf>ehd; 
Njjpapl;lvdf;F mspf;fg;gl;l Nehahspf;fhd jfty; jhs; kw;Wk; 
jfty; mspf;fg;gl;l xg;Gjy; gbtj;jpy; mlq;fpatpguq;fs; gw;wpgbj;J 
Ghpe;J nfhz;Ls;Nsd;.  kUj;Jth; Nghjpa kw;Wk; tphpthdt pjj;jpy; 
vd; gq;Nfw;G gw;wpj;  jPh;khdpf;f vdf;Fg; Nghjpa Neuk; ,Ue;jJ. 
 ,e;jkUj;Jt Ma;Telj;jg;gl;l kpf Kf;fpkhdjhf vd; 
kUj;Jthpd; Fwpg;Gfis ehd; gpd;gw;WNtd;.  ve;j fhuzKk; 
mspf;fhky;> vdf;F ve;j e\;lKk; Vw;glhky; ve;j Neuj;jpYk; Ma;it 
tpl;Ltpyf vdf;F chpik cz;L. 
 ,e;jkUj;Jt Ma;tpy; Nrfhpf;fg;gLk; vdJ nrhe;j jfty;> 
Fwpg;ghf vdJ kUj;Jt nufhh;Lfspy; vdJngah; kw;Wk; ghypdk; 
kw;Wk; ,dk; Fwpf;fg;gLk; vd;gjw;F ehd; rk;kjpf;fpNwd; ,e;jjfty; 
MdJ 
1. vyf;l;uhdpfy; Kiwapy; my;yJxUgFjpfhfpjtbtpy; 
gjpTnra;ag;gLk; gj;jpukhfitf;fg;gLk; kw;Wk; 
kjpg;gPLnra;ag;gLk;. 
2. tpQ;Qhd kjpg;gPL kw;Wk; $Ljy; tpQ;Qhd cgNahfj;jpw;fhf 
kw;Wk; mspf;fg;gLk;. 
3. cfe;j Njrpa kw;Wk; rh;tNjr nuFNyl;lhp mjhhpl;bfSf;F 
mDg;gg;gLk;. 
,NjhL kl;Lkpd;wp mq;fPfhpf;fg;gl;l gpujpepjpfs; vdJ nrhe;j 
tpguq;fs; cldhd kUj;Jt nufhh;Lfis ghpNrhjpf;fyhk;.  tpQ;Qhd 
kjpg;gPL kw;Wk; kUj;Jt Ma;tpd; nray; jpwDf;fhf jftiy 
KOikahf rhpahfg; ghpkhw;wk; nra;a ,J cjTfpwJ. 
 ehd; ,e;jMa;tpy; ,Jtiu gq;Nfw;W ,Uf;ftpy;iy kw;Wk; ,e;j 
Ma;T Muk;gpf;Fk; Kd;G 30 ehl;fspy; ehd; kw;nwhU Ma;tpy; 
gq;Nfw;wpUf;ftpy;iy vd;gij cWjp nra;fpNwd;. 
 Nehahspf;fhd jfty; jhspd; xU mry; cld; ifna*j;jjpl 
jfty; mspf;fg;gl;l xg;Gjy; gbtj;ij ehd; ngw;Ws;Nsd;. 
Nehahsp: 
  
ngah; nghpa vOj;Jfspy; ifnaOj;J   Njjp 
rhl;rp: 
  
ngah; nghpavOj;Jfspy;  ifnaOj;J   Njjp 
Nehahspf;F cwTKiw: 
ehd; lhf;lh;       Nkw;fz;;l 
ngaUila Nehahspf;F Ma;tpd; Nehf;fk; kw;Wk; jd;ikgw;wp 
tpsf;fpAs;Nsd; vd;gij cWjp nra;fpNwd;.  NkYk; ehd; midj;J 
Ma;Trk;ge;jg;gl;l Nfs;tpfSf;Fk; gjpy;fs; mspj;Js;Nsd;.  kw;Wk; 
Ma;tpd; epge;jidfis mth;fSf;F tpsf;fpAs;Nsd; vd;gij cWjp 
nra;fpNwd;. 
kUj;Jth;: 
ngah; nghpa vOj;Jfspy;  ifnaOj;J   Njjp 
  
 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
Name:      Serial No: 
Age:      Lab No: 
Sex:      OP/IP No: 
Education:     D.O.A: 
Occupation:     D.O.D: 
Income:     Provisional Diagnosis: 
Address: 
Chief complaints: 
   Fever 
   Dysurea 
   Frequency    
   Urgency   
   Lower abdominal/ flank pain 
H/O Present illness: 
Associated conditions- instrumentation/ surgery in urinary tract 
   Calculi  
   Diabetes mellitus 
   Chronic kidney and liver diseases 
   Benign Prostatic Hypertrophy 
   Pregnancy 
 Immuno compromised state 
Treatment History:  H/O anti biotic intake, duration  
Past History:   H/O Similar episode in the past  
    Instrumentation/ surgery in urinary tract 
Family History: 
Personal History: 
General Examination: Stature, nourishment, anaemia, jaundice, cyanosis, clubbing, 
     lymphadenopathy, pedal edema.  
Vital signs:  Temperature, pulse rate, respiratory rate, blood pressure. 
Systemic examination: Abdomen  
Inspection:  shape of the abdomen  
   Position of the umbilicus 
   Movements of the abdominal wall 
   Skin and surface of the abdomen  
Palpation  : Mass  
    Tenderness (Suprapubic) 
   Rigidity  
   Organomegaly 
Percussion   : Any free fluid  
Auscultation  : Bowel sounds  
     Bruit 
Examination of groin and genital region  
P/V: 
P/R: 
Examination of other systems  
CVS:              RS;               CNS:   
 
 
Definitive Diagnosis 
WORKSHEET 
 
Specimen:    Urine  
Method of collection : MSU/Indwelling catheter/Cystoscope/Suprapubic 
aspiration 
I. Macroscopic Examination: Color  
    Turbidity 
II. Microscopic Examination: Wet mount  
    Gram staining 
III. Culture    : Nutrient agar 
      MacConkey agar 
       Blood agar 
                                          CLED agar 
IV. Biochemical Reactions: 
Gram staining   : 
Motility   : 
Catalase   : 
Sugar fermentation tests : 
Arginine hydrolysis test  : 
Special Tests: 
Micro organism isolated : 
V. Anti Microbial Susceptibility test: 
VI. Screening for HLGR  1. Antibiogram(resistant with 120µg disc o   gentamicin, 
E-test , agar dilution test 
VII  Confirmation of HLGR and molecular characterization by genotypic method  
(PCR) 
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1 3970 30 M E.faecalis-U UTI S R R R R S S s aac(6)-Ie-aph(2)-Ia. 
2 1592 65 F E.faecium-P LEG ULCER R S S R R S S s aac(6)-Ie-aph(2)-Ia. 
3 3339 8 MON Fch E.faecalis-B PUO R R S S R S S S aac(6)-Ie-aph(2)-Ia. 
4 4012 18 M E.faecalis-U CKD S S R S S R S S  
5 1603 64 Mch E.faecalis-P INJURY S R R S R S S S aac(6)-Ie-aph(2)-Ia. 
6 1634 54 F E.faecalis-P 
DIABETIC 
ULCER 
S R R R S S S S  
7 4108 69 Mch E.faecium-U UTI R R S R R S R S aac(6)-Ie-aph(2)-Ia. 
8 1643 29 F E.faecalis-U UTI S S R S S S S S  
9 3372 67 Fch E.faecalis-B PUO S R R S S S S S  
10 4302 51 M E.faecalis-U UTI R R S S R S R S aac(6)-Ie-aph(2)-Ia. 
11 3398 7 Mch E.faecium-B PUO R R R R R S S S aac(6)-Ie-aph(2)-Ia. 
12 4318 71 F E.faecalis-U UTI S R R S S S S S  
13 3409 60 M E.faecalis-B PUO S S R R R S S S aac(6)-Ie-aph(2)-Ia. 
14 3421 19 F E.faecalis-B 
ENTERIC 
FEVER 
S R R S R R R R aac(6)-Ie-aph(2)-Ia. 
15 1704 57 F E.faecalis-P 
WOUND 
INFECTION 
S R R S S S S R  
16 1726 44 F E.faecium-WS POST OP WI R R S R S S S S  
17 4354 74 F E.faecalis-U UTI R S S S R S S S aac(6)-Ie-aph(2)-Ia. 
18 1765 38 M E.faecalis-P 
ABSCESS-
THIGH 
S R R S R S S S aac(6)-Ie-aph(2)-Ia. 
19 4390 46 M E.faecalis –U UTI R S S R R S S S aac(6)-Ie-aph(2)-Ia. 
20 1801 65 F E.faecalis-WS 
WOUND 
INFECTION 
S R R R S S S S  
21 4441 60 F E.faecalis-U UTI S R R S S S S S  
22 4469 55 M E.faecium-P ABSCESS R R R R R S S S aac(6)-Ie-aph(2)-Ia. 
23 4482 16 M E.faecalis-U UTI S R R R S S S S  
24 4507 62 M E.faecalis –U PUO R R S R S S S S  
25 1857 19 F E.faecalis-P DM-ULCER S S R S R S S S aac(6)-Ie-aph(2)-Ia. 
26 4568 45 F E.faecalis-U CKD R R R S R S S S aac(6)-Ie-aph(2)-Ia. 
27 3488 19 M E.faecalis-B PUO S R R S R S S S aac(6)-Ie-aph(2)-Ia. 
28 1902 53 M E.faecalis-P 
ABSCESS-LT 
LEG 
S R S S S S R S  
29 3503 69 F E.faecium-B PUO R R R R R S R S aac(6)-Ie-aph(2)-Ia. 
30 4605 67 M E.faecalis-U CYSTITIS S R R R S S S S  
31 1989 31 F E.faecium-P INJURY-RA R R S R R S S S aac(6)-Ie-aph(2)-Ia. 
32 3575 50 F E.faecalis –B FFE R S S R S S S S  
33 4684 7 Fch E.faecalis-U PUO S R R S R R S S aac(6)-Ie-aph(2)-Ia. 
34 3611 72 M E.faecalis –B FFE R R S S S S S S  
35 3675 12 Mch E.faecium-P ABSCESS R S S S R S S S aac(6)-Ie-aph(2)-Ia. 
36 4722 19 M E.faecalis –U UTI R S R S R S S S aac(6)-Ie-aph(2)-Ia. 
37 2008 46 M E.faecalis-WS POST OP WI S R R S R S S S aac(6)-Ie-aph(2)-Ia. 
38 3690 80 Mch E.faecalis-U 
ENTERIC 
FEVER 
S R R S S S S R  
39 4782 24 F E.faecalis-U PID S R R R S S S S  
40 2024 71 F E.faecalis-WS 
WOUND 
INFECTION 
S R R S R S R S aac(6)-Ie-aph(2)-Ia. 
41 2046 60 F E.faecalis-P ABSCESS S S R S S S S S  
42 2111 20 M E.faecalis –P 
WOUND 
INFECTION 
S S S S R S S S aac(6)-Ie-aph(2)-Ia. 
43 2243 62 F E.faecalis-WS POST OP WI S R S S R S S S aac(6)-Ie-aph(2)-Ia. 
44 2279 7 Mch E.faecalis-P ULCER S R R R R S S S aac(6)-Ie-aph(2)-Ia. 
45 4814 31 F E.faecalis-U UTI R R R R S S S S  
46 3732 52 F E.faecalis-U SEPTICEMIA R S S S R S S S aac(6)-Ie-aph(2)-Ia. 
47 4856 15 M E.faecium –P ABSCESS R R S R R S S S aac(6)-Ie-aph(2)-Ia. 
48 4912 13 F E.faecalis-U PUO S R R R S S S S  
49 5045 47 M E.faecalis –U UTI R R R R R S R S aac(6)-Ie-aph(2)-Ia. 
50 2318 24 F E.faecium-P ULCER R S R R S S S R  
51 2434 5 Mch E.faecalis-P 
WOUND 
INFECTION 
S R R S R R S R aac(6)-Ie-aph(2)-Ia. 
52 5132 52 F E.faecalis –U PUO S R R S S S S R  
53 5189 33 M E.faecalis-U CKD R R S R S S S R  
54 2566 63 M E.faecium-WS 
SURGICAL 
SITE 
INFECTION 
R R R R R S S S aac(6)-Ie-aph(2)-Ia. 
55 3817 52 M E.faecium-B SEPSIS R R R R R S S S aac(6)-Ie-aph(2)-Ia. 
56 2610 28 M E.faecalis-WS ULCER S S R S S S S S  
57 3972 20 F E.faecium-U PUO R S R R R R R S aac(6)-Ie-aph(2)-Ia. 
58 4015 5 Mch E.faecalis-U PUO S R R S R S S S aac(6)-Ie-aph(2)-Ia. 
59 2721 59 F E.faecalis –P ABSCESS R R R S R S S R aac(6)-Ie-aph(2)-Ia. 
60 5416 49 M E.faecalis-U UTI R S R S S S S R  
61 2914 17 M E.faecalis-P ULCER S R R R R S S R aac(6)-Ie-aph(2)-Ia. 
62 5603 67 F E.faecalis-U UTI S R S S R S S R aac(6)-Ie-aph(2)-Ia. 
63 3001 74 M E.faecalis-WS 
WOUND 
INFECTION 
S R R S S S S S  
64 5712 41 F E.faecium-U UTI R R S R S S S S  
65 5841 18 F E.faecium-U UTI R R S R R S S S aac(6)-Ie-aph(2)-Ia. 
66 5985 8 Fch E.faecalis-U PUO R R R R R S S R aac(6)-Ie-aph(2)-Ia. 
67 3074 51 F E.faecalis-P 
WOUND 
INFECTION 
S S S S R S S R aac(6)-Ie-aph(2)-Ia. 
68 6092 26 M E.faecalis-U UTI S R R S S S S R  
69 6149 57 M E.faecium-U CKD R S R R R S R R aac(6)-Ie-aph(2)-Ia. 
70 4235 7 Mch E.faecalis-U SEPSIS R R R R S S S R  
71 6212 25 M E.faecium-U PID R R R R R S S S aac(6)-Ie-aph(2)-Ia. 
72 6336 45 M E.faecalis –U PUO S S S S R S S S aac(6)-Ie-aph(2)-Ia. 
73 3118 7 Mch E.faecalis-WS POST OP WI S R R S R S S R aac(6)-Ie-aph(2)-Ia. 
74 3190 18 M E.faecalis -WS WOUND-LL S S R R R S S R aac(6)-Ie-aph(2)-Ia. 
75 4444 49 M E.faecium-U FFE R R S R S S S S  
76 3263 28 F E.faecalis-WS ULCER R S S R R R S R aac(6)-Ie-aph(2)-Ia. 
77 6474 72 M E.faeium-U UTI R R R R R S R S aac(6)-Ie-aph(2)-Ia. 
78 6510 39 M E.faecalis-U UTI S R R S R S S R aac(6)-Ie-aph(2)-Ia. 
79 6596 3 months Mch E.faecalis-U SEPTICEMIA S R R S R S S S aac(6)-Ie-aph(2)-Ia. 
80 4613 50 M E.faecalis-U 
ENTERIC 
FEVER 
S R R S R S S R aac(6)-Ie-aph(2)-Ia. 
81 6640 39 F E.faecium-U PID R R S R R S R R aac(6)-Ie-aph(2)-Ia. 
82 6712 3 M E.faecalis-U FFE S S R R S S S R  
83 3352 26 M E.faecalis-WS 
WOUND 
INFECTION 
S R R S R S S S aac(6)-Ie-aph(2)-Ia. 
84 3411 69 M E.faecalis-P 
CVA WITH 
ULCER 
S R R S R S S S aac(6)-Ie-aph(2)-Ia. 
85 3619 43 M E.faecium-P CELLULITIS R R R R S S S S  
86 5114 27 M E.faecium-U UTI R R S R S S S S  
87 6875 66 M E.faecalis-U UTI S R R R S S S S  
88 6891 8 Mch E.faecalis-P PUO S S S S R S S R aac(6)-Ie-aph(2)-Ia. 
89 3706 44 M E.faecalis-P ULCER S R R S R S S R aac(6)-Ie-aph(2)-Ia. 
90 5484 65 M E.faecium-P PUS S R R R R R R S aac(6)-Ie-aph(2)-Ia. 
91 3784 3 Mch E.faecalis-WS 
WOUND 
INFECTION 
S R R S R S S R aac(6)-Ie-aph(2)-Ia. 
92 6959 30 M E.faecium-U UTI S R R R S S S R  
93 5808 14 M E.faecalis-P PUS S S S S R R S S aac(6)-Ie-aph(2)-Ia. 
94 6992 43 M E.faecalis-U PUO S R R R R S R R aac(6)-Ie-aph(2)-Ia. 
95 3819 71 M E.faecalis-WS POST OP WI R R R R R S S S aac(6)-Ie-aph(2)-Ia. 
96 7013 25 M E.faecalis-P ABSCESS S R R S R S S R aac(6)-Ie-aph(2)-Ia. 
97 3856 18 F E.faecium-P ABSCESS S S S R S S R S  
98 3872 50 F E.faecium-WS 
WOUND 
INFECTION 
S R R R S S S R  
99 7046 6 Fch E.faecalis-U UTI S R S R R R S S aac(6)-Ie-aph(2)-Ia. 
100 6111 11 Mch E.faecalis-P PUS S S S R S S S R  
101 3892 24 M E.faecium-WS 
WOUND 
INFECTION 
R R R R R S R R aac(6)-Ie-aph(2)-Ia. 
102 6179 19 M E.faecalis –U UTI S R R S R R S S aac(6)-Ie-aph(2)-Ia. 
103 3900 57 M E.faecalis-P CHRONIC OM S R R S R S S R aac(6)-Ie-aph(2)-Ia. 
104 6202 50 M E.faecalis-P UTI S R R R R S S S aac(6)-Ie-aph(2)-Ia. 
 
MADURAI MEDICAL COLLEGE
MADt]RAI, TAM ILNADU, INDIA .625 02O V
i
Urkund Analysis Result 
Analysed Document: INTRO to CONCLU.docx (D31324476)
Submitted: 10/15/2017 10:29:00 AM 
Submitted By: shrianand2010@yahoo.com 
Significance: 10 % 
Sources included in the report: 
review of literature.docx (D31286984) 
methods &material (2).docx (D31286982) 
dddiscussion.docx (D31286871) 
A STUDY OF ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ENTEROCOCCUS SPECIES 
WITH SPECIAL REFERENCE TO VANCOMYCIN RESISTANCE BY PHENOTYPIC AND 
GENOTYPIC METHODS FROM VARIOUS CLINICAL SAMPLES IN A TERTIARY CARE 
HOSPITAL.docx (D30298042) 
Instances where selected sources appear: 
20 
U R K N DU
CERTIFICATE –II 
 
This is certify that this dissertation work titled   A STUDY ON 
DETECTION OF HIGH LEVEL GENTAMICIN RESISTANT AMONG 
ENTEROCOCCAL SPECIES AND ITS MOLECULAR   
CHARACTERIZATION IN A TERTIARY CARE CENTRE 0f the 
candidate Dr. J. Vijay anand with registration Number 2015141102 for the 
award of M.D; in the branch of MICROBIOLOGY. I personally verified the 
urkund .com website for the purpose of plagiarism check. I found that the 
uploaded thesis file contains from introduction to conclusion pages and result 
shows 10% percentage of plagiarism in the dissertation. 
 
 
Guide & supervisor sign with seal 
 
 
 
 
 
 
